T	O
cell	O
response	O
to	O
Epstein-Barr	B-protein
virus	I-protein
transactivators	I-protein
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O

Implication	O
of	O
viruses	O
such	O
as	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
in	O
rheumatoid	O
arthritis	O
pathogenesis	O
has	O
been	O
suspected	O
on	O
the	O
basis	O
of	O
several	O
indirect	O
observations	O
,	O
but	O
thus	O
far	O
,	O
a	O
direct	O
link	O
between	O
EBV	O
and	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
provided	O
.	O

Here	O
we	O
show	O
that	O
a	O
large	O
fraction	O
of	O
T	B-cell_type
cells	I-cell_type
infiltrating	O
affected	O
joints	O
from	O
a	O
patient	O
with	O
chronic	O
rheumatoid	O
arthritis	O
recognizes	O
two	O
EBV	B-protein
transactivators	I-protein
(	O
BZLF1	B-protein
and	O
BMLF1	B-protein
)	O
in	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
-restricted	O
fashion	O
.	O

Responses	O
to	O
these	O
EBV	B-protein
antigens	I-protein
by	O
synovial	O
lymphocytes	O
from	O
several	O
other	O
chronic	O
rheumatoid	O
arthritis	O
patients	O
were	O
readily	O
detectable	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O

They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	B-protein
transactivating	I-protein
factors	I-protein
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O

T	NULL
Cell	NULL
Response	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Transactivators	NULL
in	NULL
Chronic	NULL
Rheumatoid	NULL
Arthritis	NULL
By	NULL
Emmanuel	NULL
Scotet	NULL
,	NULL
*	NULL
Jacques	NULL
David-Ameline	NULL
,	NULL
*	NULL
Marie-Alix	NULL
Peyrat	NULL
,	NULL
*	NULL
Agnes	NULL
Moreau-Aubry	NULL
,	NULL
*	NULL
Delphine	NULL
Pinczon	NULL
,	NULL
``	NULL
*	NULL
Annick	NULL
Lim	NULL
,	NULL
*	NULL
Jos	NULL
Even	NULL
,	NULL
t	NULL
Gilbert	NULL
Semana	NULL
,	NULL
$	NULL
Jean-Marie	NULL
Berthelot	NULL
,	NULL
)	NULL
Richard	NULL
Breathnach	NULL
,	NULL
*	NULL
Marc	NULL
Bonneville	NULL
,	NULL
*	NULL
and	NULL
Elisabeth	NULL
Houssaint*	NULL
From	NULL
*	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
U241	NULL
,	NULL
Institut	NULL
de	NULL
Biologie	NULL
,	NULL
44035	NULL
Nantes	NULL
Cedex	NULL
O1	NULL
;	NULL
*Institut	NULL
Pasteur	NULL
75024	NULL
Paris	NULL
;	NULL
$	NULL
SCentre	NULL
Régional	NULL
de	NULL
Transfusion	NULL
Sanguine	NULL
,	NULL
35000	NULL
Rennes	NULL
;	NULL
and	NULL
Service	NULL
de	NULL
Rhumatologie	NULL
,	NULL
CHU	NULL
,	NULL
44035	NULL
Nantes	NULL
Cedex	NULL
O1	NULL
,	NULL
France	NULL
.	NULL

Summary	NULL
Rheumatoid	NULL
arthritis	NULL
is	NULL
a	NULL
multistep	NULL
disorder	NULL
associated	NULL
with	NULL
autoimmune	NULL
features	NULL
of	NULL
yet	NULL
unknown	NULL
ctiology	NULL
.	NULL

Implication	NULL
of	NULL
viruses	NULL
such	NULL
as	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
pathogenesis	NULL
has	NULL
been	NULL
suspected	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
several	NULL
indirect	NULL
observations	NULL
,	NULL
but	NULL
thus	NULL
far	NULL
,	NULL
a	NULL
direct	NULL
link	NULL
between	NULL
EBV	NULL
and	NULL
rheumatoid	NULL
arthritis	NULL
has	NULL
not	NULL
been	NULL
provided	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
a	NULL
large	NULL
fraction	NULL
of	NULL
T	NULL
cells	NULL
infiltrating	NULL
affected	NULL
joints	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
recognizes	NULL
two	NULL
EBV	NULL
transactivators	NULL
(	NULL
BZLF1	NULL
and	NULL
BMLF1	NULL
)	NULL
in	NULL
a	NULL
major	NULL
histocompatibility	NULL
complex-restricted	NULL
fashion	NULL
.	NULL

Responses	NULL
to	NULL
these	NULL
EBV	NULL
antigens	NULL
by	NULL
synovial	NULL
lymphocytes	NULL
from	NULL
several	NULL
other	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
patients	NULL
were	NULL
readily	NULL
detectable	NULL
.	NULL

Thus	NULL
these	NULL
results	NULL
suggest	NULL
a	NULL
direct	NULL
contribution	NULL
of	NULL
EBV	NULL
to	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
pathogenesis	NULL
.	NULL

They	NULL
also	NULL
demonstrate	NULL
for	NULL
the	NULL
first	NULL
time	NULL
the	NULL
occurrence	NULL
of	NULL
T	NULL
cell	NULL
responses	NULL
against	NULL
EBV	NULL
transactivating	NULL
factors	NULL
,	NULL
which	NULL
might	NULL
be	NULL
central	NULL
in	NULL
the	NULL
control	NULL
of	NULL
virus	NULL
reactivation	NULL
.	NULL

heumatoid	NULL
arthritis	NULL
(	NULL
RA	NULL
)	NULL
!	NULL

is	NULL
an	NULL
incapacitating	NULL
disease	NULL
characterized	NULL
by	NULL
chronic	NULL
joint	NULL
inflammation	NULL
and	NULL
progressive	NULL
destruction	NULL
of	NULL
articular	NULL
structures	NULL
,	NULL
which	NULL
affects	NULL
about	NULL
1	NULL
%	NULL
of	NULL
the	NULL
population	NULL
worldwide	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Its	NULL
etiology	NULL
remains	NULL
unresolved	NULL
,	NULL
but	NULL
there	NULL
is	NULL
ample	NULL
evidence	NULL
that	NULL
T	NULL
cells	NULL
contribute	NULL
directly	NULL
to	NULL
RA	NULL
pathogenesis	NULL
.	NULL

This	NULL
is	NULL
supported	NULL
in	NULL
particular	NULL
by	NULL
(	NULL
a	NULL
)	NULL
the	NULL
widespread	NULL
T	NULL
cell	NULL
infiltration	NULL
of	NULL
affected	NULL
synovial	NULL
membranes	NULL
from	NULL
RA	NULL
patients	NULL
(	NULL
2	NULL
)	NULL
,	NULL
(	NULL
b	NULL
)	NULL
the	NULL
genetic	NULL
predisposition	NULL
of	NULL
RA	NULL
,	NULL
which	NULL
is	NULL
associated	NULL
with	NULL
certain	NULL
MHC	NULL
class	NULL
H	NULL
haplotypes	NULL
(	NULL
3-7	NULL
)	NULL
,	NULL
and	NULL
(	NULL
0	NULL
)	NULL
the	NULL
beneficial	NULL
effects	NULL
of	NULL
T	NULL
cell-depleting	NULL
treatments	NULL
in	NULL
RA	NULL
patients	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Despite	NULL
this	NULL
,	NULL
the	NULL
specificity	NULL
of	NULL
T	NULL
cells	NULL
infiltrating	NULL
RA	NULL
lesions	NULL
and	NULL
their	NULL
pathogenicity	NULL
at	NULL
late	NULL
stages	NULL
of	NULL
the	NULL
disease	NULL
remain	NULL
obscure	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
the	NULL
first	NULL
issue	NULL
,	NULL
several	NULL
candidate	NULL
antigens	NULL
recognized	NULL
by	NULL
synovial	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
pro-posed	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
a	NULL
pathogenic	NULL
role	NULL
of	NULL
T	NULL
cell-mediated	NULL
immune	NULL
responses	NULL
against	NULL
connective	NULL
tissue	NULL
proteins	NULL
such	NULL
as	NULL
type	NULL
II	NULL
collagen	NULL
1s	NULL
supported	NULL
by	NULL
the	NULL
occurrence	NULL
of	NULL
increased	NULL
proliferative	NULL
responses	NULL
to	NULL
these	NULL
Ag	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
as	NULL
compared	NULL
to	NULL
PBL	NULL
in	NULL
RA	NULL
patients	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Besides	NULL
endogenous	NULL
compounds	NULL
,	NULL
several	NULL
arthritogenic	NULL
Ag	NULL
of	NULL
mycobacterial	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
BLC	NULL
,	NULL
B	NULL
lymphoblastoid	NULL
cells	NULL
;	NULL
RA	NULL
,	NULL
theu-matord	NULL
arthritis	NULL
;	NULL
SFL	NULL
,	NULL
synovial	NULL
fluid	NULL
lymphocytes	NULL
;	NULL
SML	NULL
,	NULL
synovial	NULL
membrane-derived	NULL
lymphocytes	NULL
.	NULL

origin	NULL
,	NULL
such	NULL
as	NULL
stress	NULL
proteins	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
elicit	NULL
synovial	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
some	NULL
RA	NULL
patients	NULL
,	NULL
although	NULL
the	NULL
importance	NULL
of	NULL
stress	NULL
proteins	NULL
in	NULL
synovial	NULL
T	NULL
cell-mediated	NULL
responses	NULL
against	NULL
mycobacteria	NULL
still	NULL
remains	NULL
controversial	NULL
{	NULL
12-15	NULL
}	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
variety	NULL
of	NULL
viruses	NULL
have	NULL
been	NULL
proposed	NULL
as	NULL
RA	NULL
causative	NULL
agents	NULL
(	NULL
1	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
EBV	NULL
has	NULL
long	NULL
been	NULL
linked	NULL
to	NULL
RA	NULL
on	NULL
theoretical	NULL
grounds	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
because	NULL
of	NULL
the	NULL
existence	NULL
of	NULL
shared	NULL
epitopes	NULL
between	NULL
EBV	NULL
proteins	NULL
and	NULL
RA	NULL
autoantigens	NULL
)	NULL
and	NULL
from	NULL
clinical	NULL
studies	NULL
suggesting	NULL
in	NULL
particular	NULL
increased	NULL
anti-EBV	NULL
serological	NULL
responses	NULL
in	NULL
a	NULL
fraction	NULL
of	NULL
RA	NULL
patients	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

However	NULL
the	NULL
physiopathological	NULL
relevance	NULL
of	NULL
these	NULL
observations	NULL
is	NULL
still	NULL
unclear	NULL
,	NULL
particularly	NULL
because	NULL
no	NULL
evidence	NULL
for	NULL
anti-EBV	NULL
responses	NULL
within	NULL
RA	NULL
lesions	NULL
have	NULL
been	NULL
provided	NULL
thus	NULL
far	NULL
.	NULL

The	NULL
pathogenicity	NULL
of	NULL
T	NULL
cells	NULL
at	NULL
late	NULL
stages	NULL
of	NULL
RA	NULL
is	NULL
also	NULL
a	NULL
controversial	NULL
issue	NULL
.	NULL

On	NULL
the	NULL
one	NULL
hand	NULL
,	NULL
both	NULL
the	NULL
extensive	NULL
diversity	NULL
of	NULL
the	NULL
TCRs	NULL
expressed	NULL
by	NULL
synovial	NULL
lymphocytes	NULL
isolated	NULL
from	NULL
most	NULL
chronic	NULL
RA	NULL
patients	NULL
(	NULL
18	NULL
)	NULL
and	NULL
the	NULL
evidence	NULL
for	NULL
joint	NULL
destruction	NULL
and/or	NULL
active	NULL
synovitis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
local	NULL
lymphoid	NULL
infiltrate	NULL
in	NULL
animal	NULL
models	NULL
and	NULL
in	NULL
humans	NULL
(	NULL
19	NULL
)	NULL
argues	NULL
against	NULL
a	NULL
major	NULL
role	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
perpetuation	NULL
of	NULL
RA	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
a	NULL
specific	NULL
Ag-driven	NULL
'T	NULL
cell	NULL
recruitement	NULL
to	NULL
the	NULL
joints	NULL
at	NULL
late	NULL
stages	NULL
of	NULL
RA	NULL
is	NULL
indirectly	NULL
supported	NULL
by	NULL
studies	NULL
demonstrating	NULL
oligoclonal	NULL
T	NULL
cell	NULL
expansions	NULL
within	NULL
the	NULL
affected	NULL
joints	NULL
of	NULL
several	NULL
chronic	NULL
RA	NULL
patients	NULL
(	NULL
18	NULL
)	NULL
.	NULL

1791	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
+	NULL
0022-1007/96/117/1791/10	NULL
$	NULL
2.00	NULL
Volume	NULL
184	NULL
November	NULL
19	NULL
%	NULL
6	NULL
1791-1800	NULL
Table	NULL
1	NULL
.	NULL

Patients	NULL
1	NULL
and	NULL
19	NULL
CDR3RB	NULL
TCR	NULL
Features	NULL
,	NULL
Frequency	NULL
,	NULL
and	NULL
HLA	NULL
Restriction	NULL
of	NULL
Autologous	NULL
BLC-reactive	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clones	NULL
Derived	NULL
from	NULL
Chronic	NULL
RA	NULL
TCR	NULL
BVBJ	NULL
Percentage	NULL
Percentage	NULL
HLA	NULL
T	NULL
cell	NULL
clone	NULL
composition	NULL
length	NULL
{	NULL
aa	NULL
)	NULL
of	NULL
SFL*	NULL
of	NULL
PBL*	NULL
restriction	NULL
Patient	NULL
1	NULL
A2.10	NULL
BV2BJ	NULL
182	NULL
8	NULL
5.6	NULL
<	NULL
0.2	NULL
A*0201	NULL
A2.19	NULL
BV2DBJ253	NULL
8	NULL
1.5	NULL
<	NULL
0.2	NULL
B*4002	NULL
A2.3	NULL
BV2BJ2S7	NULL
8	NULL
4.0	NULL
<	NULL
0.2	NULL
B*4002	NULL
A2.8	NULL
BV2BJ2S7	NULL
8	NULL
4.0	NULL
<	NULL
0.2	NULL
B*4002	NULL
AZ.1	NULL
BV2BJ2S87	NULL
8	NULL
4.0	NULL
<	NULL
(	NULL
0.2	NULL
B*4002	NULL
A2.21	NULL
BV2BJ183	NULL
9	NULL
<	NULL
0.2	NULL
<	NULL
0.2	NULL
B*4002	NULL
A2.4	NULL
BV2BJ255	NULL
10	NULL
2.0	NULL
<	NULL
0.2	NULL
B*4002	NULL
Al4.11	NULL
BV14BJ2S7	NULL
9	NULL
<	NULL
0.2	NULL
<	NULL
0.2	NULL
B'4002	NULL
A14.7	NULL
BV14BJ2S3	NULL
11	NULL
8.8	NULL
<	NULL
0.2	NULL
B*4002	NULL
A22.28	NULL
8	NULL
1.5	NULL
<	NULL
0.2	NULL
B*4002	NULL
A22.19	NULL
BV22B	NULL
]	NULL
2S2	NULL
8	NULL
1.3	NULL
<	NULL
0.2	NULL
B'4002	NULL
A22.13	NULL
BV22BJ2S7	NULL
8	NULL
1.0	NULL
<	NULL
0.2	NULL
B*4002	NULL
A22.32	NULL
9	NULL
<	NULL
0.2	NULL
<	NULL
0.2	NULL
13*4002	NULL
A22.34	NULL
BV22BJ2S2	NULL
12	NULL
<	NULL
0.2	NULL
<	NULL
0.2	NULL
B*4002	NULL
A22.18	NULL
BV22B	NULL
]	NULL
J2S3	NULL
12	NULL
<	NULL
0.2	NULL
<	NULL
0.2	NULL
B*4002	NULL
A17.10	NULL
BV17BJ2	NULL
$	NULL
3	NULL
8	NULL
0.3	NULL
<	NULL
0.2	NULL
Cw*0102	NULL
A1l7.11	NULL
BV17BJ254	NULL
8	NULL
0.4	NULL
<	NULL
0.2	NULL
©*0102	NULL
Patient	NULL
19	NULL
B1	NULL
ND	NULL
ND	NULL
ND	NULL
ND	NULL
A*2401	NULL
B2	NULL
ND	NULL
ND	NULL
ND	NULL
ND	NULL
B*3501	NULL
B3	NULL
ND	NULL
ND	NULL
ND	NULL
ND	NULL
B*'3501	NULL
B4	NULL
ND	NULL
ND	NULL
ND	NULL
ND	NULL
B*3501	NULL
AL	NULL
T	NULL
cell	NULL
clones	NULL
listed	NULL
in	NULL
tus	NULL
table	NULL
expressed	NULL
distinct	NULL
TCRs	NULL
as	NULL
demonstrated	NULL
by	NULL
junctional	NULL
sequence	NULL
analysis	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
T	NULL
cell	NULL
clones	NULL
listed	NULL
here	NULL
represented	NULL
19	NULL
of	NULL
20	NULL
VB2*	NULL
,	NULL
5	NULL
of	NULL
10	NULL
VRBI14*	NULL
,	NULL
4	NULL
of	NULL
7	NULL
VB17*	NULL
,	NULL
and	NULL
14	NULL
of	NULL
14	NULL
VB22*	NULL
CD	NULL
#	NULL
*	NULL
T	NULL
cell	NULL
colonies	NULL
isolated	NULL
from	NULL
pa	NULL
nent	NULL
1	NULL
SFL	NULL
and	NULL
4	NULL
of	NULL
12	NULL
CDS*	NULL
T	NULL
cell	NULL
colonies	NULL
isolated	NULL
from	NULL
patient	NULL
19	NULL
(	NULL
20	NULL
)	NULL
.	NULL

*Percentage	NULL
of	NULL
SFI	NULL
.	NULL

or	NULL
PBL	NULL
expressing	NULL
TCR	NULL
-B	NULL
chains	NULL
with	NULL
the	NULL
same	NULL
VJ	NULL
combination	NULL
and	NULL
the	NULL
same	NULL
length	NULL
as	NULL
that	NULL
of	NULL
the	NULL
reactive	NULL
'T	NULL
cell	NULL
clone	NULL
,	NULL
eso-	NULL
mated	NULL
by	NULL
semiquantitative	NULL
PCB	NULL
analysis	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
evaluate	NULL
the	NULL
repertoire	NULL
diversity	NULL
and	NULL
specificity	NULL
of	NULL
T	NULL
cells	NULL
activated	NULL
during	NULL
chronic	NULL
RA	NULL
,	NULL
we	NULL
recently	NULL
studied	NULL
the	NULL
specificity	NULL
of	NULL
synovial	NULL
T	NULL
lymphocytes	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
typical	NULL
long	NULL
lasting	NULL
chronic	NULL
RA	NULL
.	NULL

Because	NULL
in	NULL
several	NULL
patients	NULL
the	NULL
majority	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
were	NULL
CD8	NULL
#	NULL
,	NULL
both	NULL
€CD4*	NULL
cells	NULL
,	NULL
which	NULL
presumably	NULL
comprise	NULL
T	NULL
cells	NULL
reactive	NULL
against	NULL
RA	NULL
susceptibility	NULL
HLA	NULL
class	NULL
II	NULL
alleles	NULL
,	NULL
and	NULL
CDS*	NULL
cells	NULL
were	NULL
analyzed	NULL
.	NULL

CD4*	NULL
and/or	NULL
CD8~	NULL
synovial	NULL
T	NULL
cell	NULL
responses	NULL
towards	NULL
autologous	NULL
and/or	NULL
allogeneic	NULL
B	NULL
lymphoblastoid	NULL
cells	NULL
(	NULL
BLC	NULL
)	NULL
expressing	NULL
one	NULL
or	NULL
several	NULL
autologous	NULL
HLA	NULL
alleles	NULL
were	NULL
detected	NULL
in	NULL
four	NULL
of	NULL
six	NULL
patients	NULL
studied	NULL
(	NULL
David-Ameline	NULL
,	NULL
J.	NULL
,	NULL
M.A	NULL
.	NULL

Peyrat	NULL
,	NULL
and	NULL
M.	NULL
Bonneville	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
,	NULL
Furthermore	NULL
,	NULL
in	NULL
two	NULL
patients	NULL
,	NULL
an	NULL
enrichment	NULL
for	NULL
autologous	NULL
BLC-reactive	NULL
cells	NULL
among	NULL
synovial	NULL
T	NULL
cells	NULL
was	NULL
evidenced	NULL
by	NULL
comparative	NULL
analyses	NULL
of	NULL
pa-tients	NULL
``	NULL
PBL	NULL
and	NULL
synovial	NULL
T	NULL
cells	NULL
(	NULL
20	NULL
;	NULL
results	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
}	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
suggested	NULL
frequent	NULL
expansions	NULL
of	NULL
cells	NULL
reactive	NULL
against	NULL
autologous	NULL
BLC	NULL
during	NULL
chronic	NULL
RA	NULL
.	NULL

Here	NULL
we	NULL
make	NULL
use	NULL
of	NULL
this	NULL
material	NULL
to	NULL
characterize	NULL
by	NULL
1792	NULL
an	NULL
expression	NULL
cloning	NULL
approach	NULL
the	NULL
antigens	NULL
recognized	NULL
by	NULL
synovial	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
these	NULL
patients	NULL
.	NULL

A	NULL
dominant	NULL
response	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
to	NULL
twa	NULL
EBV	NULL
transactivators	NULL
is	NULL
dem-onstrated	NULL
,	NULL
thus	NULL
suggesting	NULL
an	NULL
Ag-driven	NULL
recruitment	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
the	NULL
synovium	NULL
in	NULL
these	NULL
patients	NULL
and	NULL
a	NULL
possible	NULL
role	NULL
of	NULL
these	NULL
EBV-specific	NULL
T	NULL
cells	NULL
in	NULL
chronic	NULL
RA	NULL
pathogenesis	NULL
.	NULL

More	NULL
generally	NULL
,	NULL
this	NULL
study	NULL
provides	NULL
the	NULL
first	NULL
clear-cut	NULL
evidence	NULL
for	NULL
T	NULL
cell	NULL
responses	NULL
against	NULL
EBV	NULL
proteins	NULL
playing	NULL
a	NULL
key	NULL
function	NULL
during	NULL
virus	NULL
replication	NULL
.	NULL

Such	NULL
responses	NULL
might	NULL
have	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
virus	NULL
spreading	NULL
under	NULL
physiological	NULL
and	NULL
pathological	NULL
situations	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Patients	NULL
Patient	NULL
1	NULL
(	NULL
HLA-A*0201/02	NULL
,	NULL
-B*2705/4002	NULL
,	NULL
-Cw*0102/15	NULL
,	NULL
DRB1	NULL
``	NULL
*0i01/0401	NULL
,	NULL
DGQB1*0301/0501	NULL
)	NULL
had	NULL
a	NULL
typical	NULL
erosive	NULL
RA	NULL
lasting	NULL
for	NULL
6	NULL
yr	NULL
at	NULL
the	NULL
time	NULL
of	NULL
the	NULL
first	NULL
sample	NULL
collection	NULL
.	NULL

He	NULL
fulfilled	NULL
six	NULL
of	NULL
seven	NULL
critema	NULL
for	NULL
RA	NULL
defined	NULL
by	NULL
Arnett	NULL
et	NULL
al	NULL
.	NULL

(	NULL
21	NULL
)	NULL
.	NULL

Ant-EBV	NULL
T	NULL
Cell	NULL
Responses	NULL
in	NULL
Rheumatord	NULL
Arthritis	NULL
Polyarthritis	NULL
remained	NULL
active	NULL
durning	NULL
the	NULL
whole	NULL
follow-up	NULL
period	NULL
.	NULL

This	NULL
patient	NULL
received	NULL
low-dose	NULL
predmsone	NULL
{	NULL
7-12	NULL
mg/d	NULL
)	NULL
through-out	NULL
.	NULL

Synovial	NULL
find	NULL
lymphocytes	NULL
(	NULL
SFL	NULL
)	NULL
were	NULL
obtained	NULL
during	NULL
synovial	NULL
fluid	NULL
analysis	NULL
before	NULL
steroid	NULL
infiltrations	NULL
.	NULL

Synovial	NULL
membrane	NULL
lymphocytes	NULL
(	NULL
SML	NULL
)	NULL
were	NULL
obtained	NULL
during	NULL
surgery	NULL
,	NULL
performed	NULL
27	NULL
mo	NULL
after	NULL
collection	NULL
of	NULL
SFL	NULL
.	NULL

All	NULL
other	NULL
patients	NULL
fulfilled	NULL
at	NULL
least	NULL
four	NULL
out	NULL
of	NULL
seven	NULL
critena	NULL
for	NULL
RA	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Anti-EBV	NULL
serology	NULL
was	NULL
studied	NULL
in	NULL
patients	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
.	NULL

All	NULL
had	NULL
serum	NULL
antibodies	NULL
against	NULL
at	NULL
least	NULL
one	NULL
of	NULL
the	NULL
following	NULL
EBV	NULL
proteins	NULL
:	NULL
RA	NULL
nuclear	NULL
antigen	NULL
,	NULL
Epstein-Barr	NULL
nuclear	NULL
antigen	NULL
1	NULL
,	NULL
early	NULL
antigens	NULL
,	NULL
and	NULL
viral	NULL
capsid	NULL
antigens	NULL
.	NULL

These	NULL
patients	NULL
showed	NULL
dramatically	NULL
elevated	NULL
titers	NULL
of	NULL
serum	NULL
antibodies	NULL
against	NULL
early	NULL
antigens	NULL
(	NULL
range	NULL
160	NULL
to	NULL
>	NULL
640	NULL
)	NULL
.	NULL

Cells	NULL
PBL	NULL
and	NULL
SFL	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
human	NULL
serum	NULL
,	NULL
1	NULL
mM	NULL
1-glutamine	NULL
(	NULL
hereafter	NULL
referred	NULL
to	NULL
as	NULL
culture	NULL
medium	NULL
)	NULL
,	NULL
and	NULL
recombinant	NULL
IL-2	NULL
{	NULL
100	NULL
T1U/ml	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
clones	NULL
were	NULL
isolated	NULL
and	NULL
restimulated	NULL
once	NULL
a	NULL
month	NULL
as	NULL
follows	NULL
.	NULL

Synovial	NULL
T	NULL
cells	NULL
(	NULL
either	NULL
total	NULL
or	NULL
sorted	NULL
by	NULL
means	NULL
of	NULL
TCR	NULL
BV	NULL
re-gron-specific	NULL
mAb	NULL
)	NULL
were	NULL
seeded	NULL
at	NULL
0.3	NULL
cells/well	NULL
and	NULL
cultured	NULL
in	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
IL-2	NULL
{	NULL
100	NULL
TU/ml	NULL
}	NULL
,	NULL
punfied	NULL
PHA	NULL
(	NULL
leucoagglutinin	NULL
,	NULL
0.5	NULL
pg/ml	NULL
)	NULL
and	NULL
irradiated	NULL
(	NULL
30	NULL
Gy	NULL
)	NULL
allogeneic	NULL
feeder	NULL
cells	NULL
.	NULL

Such	NULL
culture	NULL
conditions	NULL
allow	NULL
the	NULL
growth	NULL
of	NULL
virtually	NULL
all	NULL
T	NULL
cells	NULL
and	NULL
do	NULL
not	NULL
introduce	NULL
any	NULL
bias	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
reper-toire	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
flow	NULL
cytometry	NULL
analysis	NULL
using	NULL
TCR	NULL
BV	NULL
region-specific	NULL
mAb	NULL
and	NULL
by	NULL
analysis	NULL
of	NULL
TCR	NULL
CDR3	NULL
length	NULL
distribution	NULL
(	NULL
22	NULL
;	NULL
Lin	NULL
,	NULL
A.	NULL
,	NULL
M.A	NULL
.	NULL

Peyrat	NULL
,	NULL
and	NULL
M.	NULL
Bonneville	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Coreceptor	NULL
phenotype	NULL
,	NULL
TCR	NULL
features	NULL
,	NULL
and	NULL
HLA	NULL
restriction	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
are	NULL
detailed	NULL
elsewhere	NULL
(	NULL
20	NULL
)	NULL
and	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Expression	NULL
Cloning	NULL
of	NULL
T	NULL
Cell	NULL
Antigens	NULL
Construction	NULL
of	NULL
the	NULL
cDNA	NULL
Library	NULL
.	NULL

-	NULL
Poly	NULL
(	NULL
A	NULL
)	NULL
!	NULL

RNA	NULL
was	NULL
prepared	NULL
from	NULL
patient	NULL
1	NULL
BLC	NULL
using	NULL
an	NULL
mRNA	NULL
purification	NULL
kit	NULL
(	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

cDNAs	NULL
were	NULL
synthesized	NULL
using	NULL
a	NULL
Zap-cDNA	NULL
synthesis	NULL
kit	NULL
(	NULL
Stratagene	NULL
Inc.	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

BstX1I	NULL
adaptators	NULL
{	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
ligated	NULL
to	NULL
the	NULL
cDNAs	NULL
.	NULL

After	NULL
size	NULL
fractionation	NULL
,	NULL
cDNAs	NULL
were	NULL
cloned	NULL
into	NULL
pcDNA3	NULL
(	NULL
In-vitrogen	NULL
)	NULL
digested	NULL
with	NULL
BstXI	NULL
.	NULL

Recombinant	NULL
plasmids	NULL
were	NULL
elec-troporated	NULL
into	NULL
Escherichia	NULL
col	NULL
Xl-1	NULL
and	NULL
selected	NULL
with	NULL
ampicillin	NULL
(	NULL
50	NULL
pg/ml	NULL
)	NULL
,	NULL
The	NULL
library	NULL
was	NULL
divided	NULL
into	NULL
288	NULL
pools	NULL
of	NULL
200	NULL
cDNA	NULL
clones	NULL
.	NULL

Each	NULL
pool	NULL
was	NULL
amplified	NULL
to	NULL
saturation	NULL
,	NULL
and	NULL
plasmid	NULL
DNA	NULL
was	NULL
extracted	NULL
by	NULL
the	NULL
alkaline	NULL
lysis	NULL
method	NULL
.	NULL

Transfection	NULL
of	NULL
COS	NULL
Cells	NULL
,	NULL
-	NULL
Transfection	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
DEAE-dextran-chloroquine	NULL
method	NULL
as	NULL
described	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
1.5	NULL
X	NULL
10	NULL
%	NULL
COS	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
plasmid	NULL
containing	NULL
the	NULL
relevant	NULL
HLA	NULL
DNA	NULL
and	NULL
100	NULL
ng	NULL
of	NULL
a	NULL
pool	NULL
of	NULL
the	NULL
cDNA	NULL
library	NULL
.	NULL

The	NULL
genomic	NULL
HLA-A*0101	NULL
,	NULL
which	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
J.	NULL
Girdlestone	NULL
(	NULL
Medical	NULL
Research	NULL
Council	NULL
,	NULL
Cam-bridge	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

was	NULL
cloned	NULL
into	NULL
pecDNA3	NULL
.	NULL

Genomic	NULL
HLA-A*0201	NULL
DNA	NULL
,	NULL
HLA-A*2401	NULL
cDNA	NULL
,	NULL
and	NULL
HLA-A*0301	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
T.	NULL
Boon	NULL
(	NULL
Ludwig	NULL
Institute	NULL
,	NULL
Brussels	NULL
,	NULL
Belgium	NULL
)	NULL
.	NULL

HLA-A*O201	NULL
was	NULL
cloned	NULL
into	NULL
pSV2	NULL
vector	NULL
,	NULL
HLA-A*2401	NULL
and	NULL
A*0301	NULL
were	NULL
in	NULL
pcDNA3	NULL
.	NULL

The	NULL
cDNA	NULL
HLA-B*3501	NULL
,	NULL
which	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
L.	NULL
Satz	NULL
(	NULL
Laboratory	NULL
of	NULL
Immunogenetics	NULL
,	NULL
Hospital	NULL
de	NULL
Clinicas	NULL
Jose	NULL
de	NULL
San	NULL
Martin	NULL
,	NULL
Buenos	NULL
Aires	NULL
,	NULL
Argentina	NULL
)	NULL
,	NULL
was	NULL
cloned	NULL
into	NULL
peDNA3	NULL
.	NULL

HLA-B*4002	NULL
and	NULL
Cw*0102	NULL
were	NULL
cloned	NULL
from	NULL
the	NULL
B	NULL
cell	NULL
cDNA	NULL
library	NULL
.	NULL

Transfectants	NULL
were	NULL
then	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
stimulate	NULL
TNF	NULL
production	NULL
by	NULL
T	NULL
cells	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Each	NULL
positive	NULL
pool	NULL
was	NULL
subcloned	NULL
into	NULL
800-1,600	NULL
bacteria	NULL
,	NULL
which	NULL
were	NULL
each	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
trigger	NULL
T	NULL
cell	NULL
clone	NULL
TNF	NULL
release	NULL
after	NULL
expression	NULL
in	NULL
COS	NULL
cells	NULL
cotransfected	NULL
with	NULL
relevant	NULL
1793	NULL
Scotet	NULL
et	NULL
al	NULL
.	NULL

HLA	NULL
DNA	NULL
.	NULL

Positive	NULL
clones	NULL
were	NULL
sequenced	NULL
by	NULL
the	NULL
dideoxy	NULL
chain	NULL
termination	NULL
method	NULL
.	NULL

T	NULL
Cell	NULL
Stimulation	NULL
Assay	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
added	NULL
to	NULL
COS	NULL
cells	NULL
24-48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
6-18	NULL
h	NULL
later	NULL
and	NULL
tested	NULL
for	NULL
TNF	NULL
content	NULL
by	NULL
measuring	NULL
culture	NULL
supernatant	NULL
cytotoxicity	NULL
to	NULL
WEHMIt64	NULL
clone	NULL
13	NULL
in	NULL
a	NULL
color-metric	NULL
assay	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Production	NULL
of	NULL
Truncated	NULL
BMLF1	NULL
or	NULL
BZLF1	NULL
cDNA	NULL
.	NULL

-	NULL
Truncated	NULL
BMLF1	NULL
cDNA	NULL
fragments	NULL
,	NULL
generated	NULL
by	NULL
partial	NULL
digests	NULL
,	NULL
were	NULL
cloned	NULL
into	NULL
peDNA3	NULL
.	NULL

pecDNA3	NULL
vector	NULL
was	NULL
also	NULL
used	NULL
to	NULL
clone	NULL
a	NULL
140-bp	NULL
fragment	NULL
after	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
ASacII	NULL
BMLFi1	NULL
fragment	NULL
with	NULL
olgonucleotides	NULL
BM1	NULL
(	NULL
5-GCGGATCCGCCACCATG-3	NULL
'	NULL
)	NULL
,	NULL
introducing	NULL
a	NULL
BamHI	NULL
site	NULL
for	NULL
cloning	NULL
and	NULL
an	NULL
internal	NULL
ATG	NULL
,	NULL
and	NULL
SP6	NULL
(	NULL
S'-ATTTAGGTGACACTATAG-3	NULL
``	NULL
)	NULL
.	NULL

Truncated	NULL
BZLFi	NULL
cDNA	NULL
fragments	NULL
,	NULL
generated	NULL
by	NULL
partial	NULL
digests	NULL
,	NULL
were	NULL
cloned	NULL
into	NULL
peDNA3	NULL
.	NULL

Peptide	NULL
Assays	NULL
Lyophilized	NULL
peptides	NULL
(	NULL
Chiron	NULL
Mimotopes	NULL
Corp.	NULL
,	NULL
Victoria	NULL
,	NULL
Australia	NULL
)	NULL
were	NULL
dissolved	NULL
at	NULL
20	NULL
mg/ml	NULL
in	NULL
DMSO	NULL
,	NULL
diluted	NULL
at	NULL
2	NULL
mg/ml	NULL
in	NULL
10	NULL
mM	NULL
acetic	NULL
acid	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

In	NULL
cytaotoxic-ity	NULL
assays	NULL
,	NULL
2.5	NULL
X	NULL
10	NULL
%	NULL
``	NULL
Cr-labeled	NULL
A2.10	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
peptides	NULL
at	NULL
various	NULL
concéntrations	NULL
,	NULL
and	NULL
``	NULL
Cr	NULL
release	NULL
was	NULL
measured	NULL
after	NULL
3	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Percentage	NULL
of	NULL
specific	NULL
lysis	NULL
was	NULL
calculated	NULL
as	NULL
described	NULL
in	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
TNF	NULL
release	NULL
assays	NULL
,	NULL
2.5	NULL
X	NULL
10+	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
5	NULL
h	NULL
with	NULL
the	NULL
peptides	NULL
at	NULL
various	NULL
concentrations	NULL
,	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
TNF	NULL
released	NULL
in	NULL
the	NULL
supernatant	NULL
was	NULL
estimated	NULL
by	NULL
the	NULL
WEHI	NULL
164	NULL
cytotoxicity	NULL
assay	NULL
.	NULL

T	NULL
Cell	NULL
Cytotoxicity	NULL
and	NULL
Proliferation	NULL
Assays	NULL
Both	NULL
kinds	NULL
of	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
cytotoxic	NULL
activity	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
toward	NULL
BLC	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
standard	NULL
4-h	NULL
``	NULL
Cr-release	NULL
assay	NULL
at	NULL
two	NULL
E/T	NULL
ratios	NULL
.	NULL

T	NULL
cell	NULL
clone	NULL
cytolytic	NULL
potential	NULL
was	NULL
estimated	NULL
by	NULL
lectin-dependent	NULL
killing	NULL
of	NULL
target	NULL
cells	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
by	NULL
evaluating	NULL
T	NULL
cell	NULL
cytotoxic	NULL
activity	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
0.5	NULL
pg/ml	NULL
of	NULL
purified	NULL
PHA	NULL
[	NULL
Ieucoagglutinin	NULL
]	NULL
)	NULL
.	NULL

Proliferative	NULL
activity	NULL
of	NULL
responder	NULL
T	NULL
cells	NULL
was	NULL
estimated	NULL
after	NULL
a	NULL
48-h	NULL
culture	NULL
of	NULL
10+	NULL
responder	NULL
cells	NULL
with	NULL
2.5	NULL
X	NULL
104	NULL
irradiated	NULL
BLC	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
rIL-2	NULL
,	NULL
followed	NULL
by	NULL
an	NULL
overnight	NULL
pulse	NULL
with	NULL
0.5	NULL
pCi	NULL
of	NULL
triti-ated	NULL
thymidine	NULL
.	NULL

COS	NULL
Transfection	NULL
Assays	NULL
Using	NULL
Polyclonal	NULL
T	NULL
Cell	NULL
Lines	NULL
Patients	NULL
'	NULL
PBL	NULL
,	NULL
SFL	NULL
,	NULL
or	NULL
SML	NULL
were	NULL
cultured	NULL
for	NULL
15	NULL
d	NULL
in	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
rIL-2	NULL
and	NULL
leucoagglutinin	NULL
.	NULL

Under	NULL
such	NULL
culture	NULL
condifions	NULL
,	NULL
no	NULL
TCR	NULL
repertoire	NULL
skewings	NULL
were	NULL
intro-duced	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
comparative	NULL
analysis	NULL
of	NULL
TCR	NULL
BV	NULL
CDR3	NULL
length	NULL
distribution	NULL
of	NULL
some	NULL
synovial	NULL
samples	NULL
before	NULL
and	NULL
after	NULL
culture	NULL
(	NULL
Lim	NULL
,	NULL
A.	NULL
,	NULL
M.A	NULL
.	NULL

Peyrat	NULL
,	NULL
and	NULL
M.	NULL
Bonneville	NULL
,	NULL
unpublished	NULL
ob-servations	NULL
}	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
colls	NULL
were	NULL
maintained	NULL
for	NULL
7	NULL
d	NULL
in	NULL
culture	NULL
medium	NULL
with	NULL
rIl-2	NULL
but	NULL
without	NULL
lectin	NULL
,	NULL
to	NULL
decrease	NULL
spontaneous	NULL
TNF	NULL
release	NULL
.	NULL

TNF	NULL
secretion	NULL
in	NULL
culture	NULL
supernatant	NULL
was	NULL
then	NULL
estimated	NULL
as	NULL
described	NULL
above	NULL
,	NULL
after	NULL
incubating	NULL
for	NULL
6	NULL
h	NULL
varying	NULL
numbers	NULL
of	NULL
responder	NULL
T	NULL
cells	NULL
(	NULL
from	NULL
10°	NULL
to	NULL
10°	NULL
)	NULL
together	NULL
with	NULL
confluent	NULL
COS	NULL
cells	NULL
transfected	NULL
24	NULL
h	NULL
earlier	NULL
with	NULL
HLA	NULL
and/or	NULL
EBV	NULL
cDNAs	NULL
.	NULL

Results	NULL
We	NULL
recently	NULL
showed	NULL
that	NULL
a	NULL
large	NULL
fraction	NULL
of	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
derived	NULL
from	NULL
two	NULL
patients	NULL
(	NULL
hereafter	NULL
referred	NULL
to	NULL
as	NULL
patients	NULL
1	NULL
and	NULL
19	NULL
)	NULL
proliferated	NULL
in	NULL
vitro	NULL
when	NULL
exposed	NULL
to	NULL
au	NULL
A	NULL
B	NULL
T	NULL
cell	NULL
-	NULL
HLA-	NULL
-	NULL
cDNA	NULL
ATG	NULL
A2.10	NULL
-	NULL
BMLF	NULL
®	NULL
*	NULL
b	NULL
l	NULL
_-	NULL
100	NULL
bp	NULL
a	NULL
10	NULL
-	NULL
ae	NULL
30	NULL
40	NULL
0	NULL
so	NULL
TNF	NULL
release	NULL
(	NULL
pg/im	NULL
!	NULL
}	NULL

0	NULL
|=	NULL
P	NULL
&	NULL
%	NULL
speciﬁc	NULL
lysis	NULL
TNF	NULL
release	NULL
(	NULL
pg/ml	NULL
)	NULL
}	NULL
L	NULL
o	NULL
<	NULL
J	NULL
Lo	NULL
saa	NULL
0	NULL
26	NULL
28	NULL
se	NULL
Peptide	NULL
concentration	NULL
(	NULL
nM	NULL
)	NULL
sa	NULL
73	NULL
100	NULL
Peptide	NULL
concentration	NULL
(	NULL
nM	NULL
)	NULL
Figure	NULL
|	NULL
1	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
antigeme	NULL
peptide	NULL
recog-+	NULL
mzed	NULL
by	NULL
the	NULL
synovial	NULL
T	NULL
cell	NULL
Hine	NULL
1	NULL
clone	NULL
AZ.10	NULL
.	NULL

(	NULL
4	NULL
)	NULL
BMLF1	NULL
recog-mtion	NULL
by	NULL
the	NULL
HLA-A*0201-Sme	NULL
N	NULL
+	NULL
restricted	NULL
T	NULL
cell	NULL
clone	NULL
A210	NULL
A210	NULL
T	NULL
cells	NULL
were	NULL
added	NULL
to	NULL
+	NULL
COS	NULL
-	NULL
cells	NULL
-	NULL
transfected	NULL
-	NULL
with	NULL
BMLFI	NULL
cDNA	NULL
and	NULL
HLA-A*OZ01	NULL
DNA	NULL
,	NULL
or	NULL
with	NULL
each	NULL
of	NULL
these	NULL
DNA	NULL
-	NULL
TNF	NULL
production	NULL
was	NULL
assessed	NULL
after	NULL
a	NULL
6-18-h	NULL
incubation	NULL
as	NULL
described	NULL
(	NULL
18	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Mapping	NULL
of	NULL
the	NULL
BMLEI	NULL
sequence	NULL
coding	NULL
for	NULL
the	NULL
antigenic	NULL
pepude	NULL
|	NULL
recogmized	NULL
by	NULL
clone	NULL
A2.10	NULL
.	NULL

BMLE1L	NULL
cDNA	NULL
fragments	NULL
were	NULL
cloned	NULL
into	NULL
peDNA3	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
abihty	NULL
to	NULL
induce	NULL
A2.10	NULL
TNF	NULL
production	NULL
after	NULL
transfection	NULL
info	NULL
COS	NULL
cells	NULL
together	NULL
with	NULL
HLA-A	NULL
``	NULL
0201	NULL
.	NULL

+	NULL
,	NULL
A210	NULL
TNF	NULL
release	NULL
>	NULL
22	NULL
pg/ml	NULL
.	NULL

-=	NULL
,	NULL
A210	NULL
TNF	NULL
release	NULL
<	NULL
1	NULL
pg/	NULL
ml	NULL
(	NULL
C	NULL
)	NULL
Induction	NULL
of	NULL
A2.10	NULL
clone	NULL
autocytotoxicity	NULL
_	NULL
by	NULL
-	NULL
synthetic	NULL
BMLF1	NULL
peptides	NULL
.	NULL

10	NULL
pepudes	NULL
(	NULL
5	NULL
O-mers	NULL
,	NULL
4	NULL
10-mers	NULL
,	NULL
and	NULL
1	NULL
11	NULL
TNF	NULL
release	NULL
Hinc	NULL
it	NULL
Sac	NULL
it	NULL
:	NULL
|	NULL
AYGHIeISnlI	NULL
mer	NULL
)	NULL
encoded	NULL
by	NULL
the	NULL
140	NULL
bp	NULL
fragment	NULL
defined	NULL
in	NULL
B	NULL
and	NULL
contaming	NULL
consensus	NULL
binding	NULL
``	NULL
anchor	NULL
``	NULL
regadues	NULL
to	NULL
HLA-A	NULL
``	NULL
0201	NULL
were	NULL
synthesized	NULL
Sigmficant	NULL
T	NULL
cell	NULL
clone	NULL
lysis	NULL
was	NULL
observed	NULL
with	NULL
peprde	NULL
GLCTLVAML	NULL
but	NULL
with	NULL
none	NULL
of	NULL
the	NULL
9	NULL
other	NULL
peptides	NULL
tested	NULL
.	NULL

Data	NULL
obtained	NULL
with	NULL
peptide	NULL
TLVAMLEETI	NULL
are	NULL
shown	NULL
as	NULL
a	NULL
negative	NULL
example	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Induction	NULL
of	NULL
A2.10	NULL
clone	NULL
TNF	NULL
release	NULL
by	NULL
synthetic	NULL
BMLFI	NULL
pepudes	NULL
.	NULL

Peptide	NULL
GLCTLVAML	NULL
but	NULL
none	NULL
of	NULL
the	NULL
9	NULL
other	NULL
peptides	NULL
tested	NULL
stunulated	NULL
production	NULL
of	NULL
TNF	NULL
by	NULL
clone	NULL
A2.10	NULL
,	NULL
Peptide	NULL
TLVAMLEETI	NULL
is	NULL
shown	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

tologous	NULL
BLC	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
autologous	NULL
BLC-reactive	NULL
clones	NULL
were	NULL
found	NULL
in	NULL
both	NULL
CD4	NULL
!	NULL

and	NULL
CD8*	NULL
T	NULL
cell	NULL
subsets	NULL
suggested	NULL
that	NULL
this	NULL
reactivity	NULL
was	NULL
a	NULL
general	NULL
feature	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
,	NULL
regardless	NULL
of	NULL
their	NULL
coreceptor	NULL
phenotype	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
establish	NULL
the	NULL
fine	NULL
specificity	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
cDNAs	NULL
from	NULL
a	NULL
patient	NULL
1	NULL
BLC	NULL
library	NULL
were	NULL
screened	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
trigger	NULL
TNF	NULL
production	NULL
by	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
after	NULL
transient	NULL
cotransfection	NULL
into	NULL
COS	NULL
cells	NULL
together	NULL
with	NULL
DNAs	NULL
encoding	NULL
the	NULL
appropriate	NULL
MHC	NULL
allele	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Because	NULL
this	NULL
approach	NULL
is	NULL
well	NULL
suited	NULL
for	NULL
cloning	NULL
MHC	NULL
class	NULL
I-	NULL
but	NULL
not	NULL
class	NULL
HI-restricted	NULL
Ags	NULL
(	NULL
23	NULL
)	NULL
,	NULL
this	NULL
analysis	NULL
focused	NULL
on	NULL
the	NULL
characterization	NULL
of	NULL
Ag	NULL
recognized	NULL
by	NULL
CDB8~T	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

Recognition	NULL
of	NULL
the	NULL
EBV	NULL
Transactivator	NULL
BMLF1	NULL
by	NULL
the	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clore	NULL
A2.10	NULL
.	NULL

A	NULL
T	NULL
cell	NULL
clone	NULL
from	NULL
patient	NULL
1	NULL
,	NULL
A2.10	NULL
,	NULL
recognizing	NULL
autologous	NULL
BLC	NULL
in	NULL
an	NULL
HLA-A*0201-restricted	NULL
fashion	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
was	NULL
analyzed	NULL
first	NULL
.	NULL

Using	NULL
the	NULL
COS	NULL
transfection	NULL
approach	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
,	NULL
we	NULL
identified	NULL
2	NULL
out	NULL
of	NULL
270	NULL
cDNA	NULL
pools	NULL
that	NULL
induced	NULL
TNF	NULL
production	NULL
by	NULL
clone	NULL
A2.10	NULL
after	NULL
cotransfection	NULL
with	NULL
HLA-A¥*0201	NULL
DNA	NULL
.	NULL

Out	NULL
of	NULL
800	NULL
clones	NULL
derived	NULL
from	NULL
one	NULL
positive	NULL
pool	NULL
,	NULL
one	NULL
1,591-bp	NULL
cDNA	NULL
induced	NULL
TNF	NULL
production	NULL
by	NULL
A2.10	NULL
cells	NULL
when	NULL
cotransfected	NULL
with	NULL
HLA-A*0201	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

Its	NULL
sequence	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
an	NULL
EBV	NULL
gene	NULL
,	NULL
BMLF1	NULL
,	NULL
encoding	NULL
a	NULL
43	NULL
%	NULL
9-amino	NULL
acid	NULL
protein	NULL
expressed	NULL
during	NULL
the	NULL
early	NULL
stage	NULL
of	NULL
the	NULL
virus	NULL
replicative	NULL
cycle	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
transactivating	NULL
properties	NULL
of	NULL
the	NULL
BMLF1	NULL
product	NULL
(	NULL
26	NULL
)	NULL
,	NULL
this	NULL
protein	NULL
could	NULL
upregulate	NULL
the	NULL
expression	NULL
of	NULL
endogenous	NULL
Ag	NULL
recognized	NULL
in	NULL
turn	NULL
by	NULL
the	NULL
synovial	NULL
T	NULL
cell	NULL
clone	NULL
rather	NULL
than	NULL
being	NULL
1794	NULL
recognized	NULL
itself	NULL
.	NULL

To	NULL
address	NULL
this	NULL
question	NULL
,	NULL
truncated	NULL
BMLF1	NULL
cDNAs	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
abslity	NULL
to	NULL
activate	NULL
A2.10	NULL
TNF	NULL
release	NULL
after	NULL
cotransfection	NULL
with	NULL
HLA-A*0201	NULL
DNA	NULL
.	NULL

A	NULL
BMLF	NULL
!	NULL

1	NULL
region	NULL
encoded	NULL
by	NULL
a	NULL
Hincll/Sacll	NULL
140-bp	NULL
sequence	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
stimulatory	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

Of	NULL
several	NULL
peptides	NULL
located	NULL
in	NULL
this	NULL
region	NULL
and	NULL
synthesized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
consensus	NULL
binding	NULL
capacities	NULL
to	NULL
HLA-A*0201	NULL
(	NULL
28	NULL
)	NULL
,	NULL
only	NULL
the	NULL
nonapeptide	NULL
GLCTLVAML	NULL
(	NULL
amino	NULL
acids	NULL
259-267	NULL
)	NULL
induced	NULL
autocytotoxicity	NULL
and	NULL
TNF	NULL
release	NULL
by	NULL
A2.10	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

This	NULL
formally	NULL
demonstrates	NULL
a	NULL
classic	NULL
MHC-restricted	NULL
recognition	NULL
of	NULL
the	NULL
BMLF1	NULL
protein	NULL
.	NULL

Recognition	NULL
of	NULL
the	NULL
EBV	NULL
Transactivator	NULL
BZLF1	NULL
by	NULL
the	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clone	NULL
A17.11	NULL
.	NULL

-	NULL
The	NULL
antigenic	NULL
specificity	NULL
of	NULL
an-ather	NULL
synovial	NULL
T	NULL
cell	NULL
clone	NULL
from	NULL
patient	NULL
1	NULL
,	NULL
A17.11	NULL
,	NULL
which	NULL
recognized	NULL
autologous	NULL
BLC	NULL
in	NULL
an	NULL
HLA-Cw*O102-restricted	NULL
fashion	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
was	NULL
then	NULL
studied	NULL
.	NULL

Because	NULL
this	NULL
clone	NULL
did	NULL
not	NULL
react	NULL
with	NULL
COS	NULL
cells	NULL
cotransfected	NULL
with	NULL
BMLF1	NULL
and	NULL
HLA-Cw*0102	NULL
cDNAs	NULL
,	NULL
the	NULL
cloning	NULL
strategy	NULL
described	NULL
above	NULL
was	NULL
applied	NULL
once	NULL
again	NULL
(	NULL
23	NULL
)	NULL
.	NULL

One	NULL
cDNA	NULL
,	NULL
which	NULL
conferred	NULL
recognition	NULL
of	NULL
COS	NULL
cells	NULL
by	NULL
A17.11	NULL
cells	NULL
after	NULL
cotransfection	NULL
with	NULL
HLA-Cw*0102	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
contained	NULL
a	NULL
753-bp	NULL
cDNA	NULL
insert	NULL
encoding	NULL
BZLF1	NULL
,	NULL
another	NULL
early	NULL
EBV	NULL
protein	NULL
with	NULL
transactivating	NULL
properties	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Dominant	NULL
Response	NULL
of	NULL
Synovial	NULL
T	NULL
Cells	NULL
from	NULL
Patient	NULL
1	NULL
to	NULL
EBV	NULL
Transactivators	NULL
.	NULL

-	NULL
We	NULL
then	NULL
tested	NULL
the	NULL
reactivity	NULL
toward	NULL
BMLEF1-	NULL
or	NULL
BZLF1-transfected	NULL
COS	NULL
cells	NULL
of	NULL
the	NULL
whole	NULL
panel	NULL
of	NULL
BLC	NULL
I-reactive	NULL
CD8*	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
with	NULL
a	NULL
known	NULL
HLA	NULL
restriction	NULL
element	NULL
(	NULL
A*0201	NULL
,	NULL
B*4002	NULL
,	NULL
or	NULL
Cw	NULL
``	NULL
*0102	NULL
)	NULL
and	NULL
expressing	NULL
distinct	NULL
T	NULL
cell	NULL
receptors	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Anti-EBV	NULL
T	NULL
Cell	NULL
Responses	NULL
in	NULL
Rheumatoid	NULL
Arthritis	NULL
T	NULL
cell	NULL
HLA-	NULL
cDNA	NULL
A17.11	NULL
Cw*0102	NULL
BZLFi	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
*	NULL
0	NULL
1	NULL
0	NULL
20	NULL
30	NULL
TNF	NULL
release	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
BZLFI	NULL
recognition	NULL
by	NULL
the	NULL
HLA-Cw*0102-restricted	NULL
T	NULL
cell	NULL
clone	NULL
A17.11	NULL
.	NULL

TNF	NULL
released	NULL
by	NULL
T	NULL
cell	NULL
clone	NULL
A17.11	NULL
was	NULL
measured	NULL
after	NULL
incubation	NULL
with	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
BZLFI	NULL
and	NULL
HLA-Cw*0102	NULL
cDNA	NULL
or	NULL
with	NULL
each	NULL
of	NULL
these	NULL
cDNA	NULL
.	NULL

The	NULL
expenmental	NULL
protocol	NULL
1s	NULL
the	NULL
same	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Whereas	NULL
one	NULL
other	NULL
clone	NULL
reacted	NULL
with	NULL
BZLFI	NULL
in	NULL
the	NULL
context	NULL
of	NULL
HLA-Cw*0102	NULL
(	NULL
clone	NULL
A17.10	NULL
,	NULL
Table	NULL
2	NULL
)	NULL
,	NULL
most	NULL
T	NULL
cell	NULL
clones	NULL
recognized	NULL
BZLF1	NULL
in	NULL
the	NULL
context	NULL
of	NULL
HLA-B*4002	NULL
{	NULL
representative	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
and	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
characterization	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
recognizing	NULL
BZLF1	NULL
in	NULL
the	NULL
context	NULL
of	NULL
HLA-B*4002	NULL
,	NULL
for	NULL
which	NULL
peptide	NULL
anchor	NULL
motifs	NULL
are	NULL
well	NULL
defined	NULL
(	NULL
28	NULL
)	NULL
,	NULL
allowed	NULL
us	NULL
to	NULL
determine	NULL
whether	NULL
,	NULL
similarly	NULL
to	NULL
BMLF1	NULL
,	NULL
this	NULL
transactivator	NULL
was	NULL
recognized	NULL
as	NULL
a	NULL
peptidic	NULL
antigen	NULL
presented	NULL
by	NULL
MHC	NULL
prod-ucts	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
,	NULL
BZLF1	NULL
cDNA	NULL
fragments	NULL
able	NULL
to	NULL
trigger	NULL
TNF	NULL
production	NULL
by	NULL
T	NULL
cell	NULL
clone	NULL
A14.7	NULL
after	NULL
cotransfection	NULL
with	NULL
HLA-B*4002	NULL
DNA	NULL
into	NULL
COS	NULL
cells	NULL
could	NULL
be	NULL
defined	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
,	NULL
and	NULL
a	NULL
synthetic	NULL
peptide	NULL
located	NULL
in	NULL
the	NULL
stimulatory	NULL
BZLF1	NULL
region	NULL
was	NULL
shown	NULL
to	NULL
trigger	NULL
T	NULL
cell	NULL
clone	NULL
autocytotoxicity	NULL
and	NULL
TNF	NULL
release	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

That	NULL
there	NULL
is	NULL
an	NULL
entichment	NULL
for	NULL
T	NULL
cells	NULL
reacting	NULL
against	NULL
BZLF1/BMLF1	NULL
]	NULL
antigens	NULL
within	NULL
the	NULL
inflamed	NULL
joints	NULL
of	NULL
patient	NULL
1	NULL
is	NULL
supported	NULL
by	NULL
two	NULL
lines	NULL
of	NULL
evidence	NULL
.	NULL

First	NULL
,	NULL
T	NULL
cells	NULL
expressing	NULL
TCR-B	NULL
chains	NULL
with	NULL
VB/JB	NULL
combinations	NULL
and	NULL
lengths	NULL
identical	NULL
to	NULL
those	NULL
expressed	NULL
by	NULL
EBV-reactive	NULL
T	NULL
cell	NULL
clones	NULL
accounted	NULL
for	NULL
~30	NULL
%	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
only	NULL
a	NULL
minute	NULL
fraction	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
from	NULL
patient	NULL
1	NULL
{	NULL
Table	NULL
1	NULL
}	NULL
.	NULL

Second	NULL
,	NULL
TNF	NULL
production	NULL
by	NULL
short-term	NULL
cultured	NULL
synovial	NULL
fluid	NULL
and	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
from	NULL
patient	NULL
1	NULL
induced	NULL
by	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
HLA-A*0201	NULL
,	NULL
B*4002	NULL
,	NULL
or	NULL
Cw*QO102	NULL
DNAs	NULL
together	NULL
with	NULL
either	NULL
BZLF	NULL
!	NULL

1	NULL
or	NULL
BMLF1	NULL
cDNAs	NULL
differ	NULL
dramatically	NULL
:	NULL
compare	NULL
the	NULL
amounts	NULL
of	NULL
TNF	NULL
released	NULL
by	NULL
synovial	NULL
as	NULL
compared	NULL
to	NULL
peripheral	NULL
blood	NULL
'	NULL
I	NULL
cells	NULL
after	NULL
exposure	NULL
to	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
BMLFIL	NULL
and	NULL
A*0201	NULL
DNAs	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
upper	NULL
leff	NULL
)	NULL
or	NULL
BZLF1	NULL
and	NULL
B*4002	NULL
DNAs	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lower	NULL
middle	NULL
)	NULL
.	NULL

Signif-icantly	NULL
,	NULL
dominant	NULL
responses	NULL
to	NULL
BZLF1/B*4002	NULL
and	NULL
BMLF1/	NULL
A*0201	NULL
were	NULL
seen	NULL
with	NULL
synovial	NULL
membrane-derived	NULL
lymphocytes	NULL
recovered	NULL
27	NULL
mo	NULL
after	NULL
the	NULL
first	NULL
sample	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
these	NULL
reactivities	NULL
are	NULL
common	NULL
and	NULL
long-lasting	NULL
features	NULL
of	NULL
synovial	NULL
lymphocytes	NULL
derived	NULL
from	NULL
patient	NULL
1	NULL
.	NULL

T	NULL
Cell	NULL
Responses	NULL
to	NULL
BMLF1/BZLF1	NULL
in	NULL
Other	NULL
Chronic	NULL
RA	NULL
Patients	NULL
.	NULL

_	NULL
An	NULL
enfichment	NULL
for	NULL
autologous	NULL
BLC-reactive	NULL
T	NULL
cells	NULL
within	NULL
the	NULL
synovium	NULL
in	NULL
another	NULL
chronic	NULL
RA	NULL
patient	NULL
(	NULL
patient	NULL
19	NULL
)	NULL
was	NULL
suggested	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
unlike	NULL
PBL	NULL
clones	NULL
,	NULL
4	NULL
of	NULL
12	NULL
randomly	NULL
chosen	NULL
CD	NULL
#	NULL
8	NULL
!	NULL
'	NULL

synovial	NULL
clones	NULL
derived	NULL
1795	NULL
Scotet	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
2	NULL
,	NULL
-	NULL
TNF	NULL
Responses	NULL
of	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clones	NULL
from	NULL
Patient	NULL
1	NULL
to	NULL
BMLF1-	NULL
or	NULL
BZLF1	NULL
transfected	NULL
COS	NULL
Cells	NULL
TNF	NULL
release	NULL
BZLF1	NULL
BMLFL	NULL
T	NULL
cell	NULL
clone	NULL
A'0201	NULL
B*4002	NULL
Cw*0102	NULL
pg/ml	NULL
A2.10	NULL
44.5	NULL
-	NULL
A2.19	NULL
-	NULL
45.8	NULL
A2.3	NULL
-	NULL
37.4	NULL
A2.8	NULL
-	NULL
39.5	NULL
A2.1	NULL
-	NULL
18.6	NULL
AZ.21	NULL
-	NULL
30.8	NULL
A24	NULL
-	NULL
1.2	NULL
Al4.11	NULL
-	NULL
6.0	NULL
A14.7	NULL
-	NULL
39.3	NULL
A22.28	NULL
-	NULL
13.0	NULL
A22.19	NULL
-	NULL
37.5	NULL
A22.13	NULL
-	NULL
25.0	NULL
A22.32	NULL
-	NULL
25.0	NULL
A22.34	NULL
-=	NULL
25.0	NULL
A22.18	NULL
-	NULL
20.0	NULL
A17.10	NULL
-	NULL
-	NULL
20.0	NULL
A17.11	NULL
-	NULL
-	NULL
13.6	NULL
TNF	NULL
production	NULL
by	NULL
T	NULL
cell	NULL
clones	NULL
was	NULL
estimated	NULL
after	NULL
incubation	NULL
with	NULL
COS	NULL
cells	NULL
tranfected	NULL
with	NULL
either	NULL
BMLF1	NULL
or	NULL
BZLF1	NULL
cDNAs	NULL
and	NULL
either	NULL
HLA-A*0201	NULL
,	NULL
~B*4002	NULL
,	NULL
or	NULL
~Cw*0102	NULL
DNAs	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
HLA/Ag	NULL
combinations	NULL
yielding	NULL
significant	NULL
TNF	NULL
produc-ton	NULL
(	NULL
0.5	NULL
pg/ml	NULL
)	NULL
by	NULL
any	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
clones	NULL
tested	NULL
.	NULL

-	NULL
,	NULL
TNF	NULL
secretion	NULL
<	NULL
0.5	NULL
pg/ml	NULL
.	NULL

from	NULL
this	NULL
patient	NULL
reacted	NULL
against	NULL
the	NULL
autologous	NULL
BLC	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
HLA	NULL
restriction	NULL
of	NULL
these	NULL
clones	NULL
was	NULL
established	NULL
(	NULL
3	NULL
clones	NULL
were	NULL
HLA-B*35	NULL
restricted	NULL
and	NULL
1	NULL
clone	NULL
was	NULL
HLA-A*24	NULL
restricted	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
we	NULL
could	NULL
evaluate	NULL
their	NULL
reactiv~	NULL
ity	NULL
toward	NULL
BZLF1	NULL
and	NULL
BMLF1	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
corresponding	NULL
cDNA	NULL
into	NULL
COS	NULL
cells	NULL
together	NULL
with	NULL
HLA-A*2401	NULL
or	NULL
-B*3501	NULL
cDNAs	NULL
.	NULL

Whereas	NULL
the	NULL
HLA-A*24-restricted	NULL
clone	NULL
reacted	NULL
against	NULL
neither	NULL
BMLF1	NULL
nor	NULL
BZLFI	NULL
{	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
all	NULL
the	NULL
HLA-B*35-restricted	NULL
F	NULL
cell	NULL
clones	NULL
turned	NULL
out	NULL
to	NULL
recognize	NULL
BZLF1	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
responses	NULL
to	NULL
BMLFI1L	NULL
and	NULL
BZLF1	NULL
were	NULL
also	NULL
studied	NULL
at	NULL
the	NULL
polyclonal	NULL
level	NULL
in	NULL
patient	NULL
19	NULL
and	NULL
in	NULL
several	NULL
HLA-A*02+	NULL
chronic	NULL
RA	NULL
patients	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
above	NULL
results	NULL
,	NULL
a	NULL
clear	NULL
TNF	NULL
response	NULL
was	NULL
detected	NULL
when	NULL
incubating	NULL
short-term	NULL
cultured	NULL
synovial	NULL
T	NULL
cells	NULL
from	NULL
patient	NULL
19	NULL
with	NULL
HLA-B*3501/BZLF1-transfected	NULL
COS	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
right	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
companson	NULL
of	NULL
the	NULL
amounts	NULL
of	NULL
TNF	NULL
released	NULL
by	NULL
PBL	NULL
and	NULL
SFL	NULL
under	NULL
these	NULL
assay	NULL
conditions	NULL
strongly	NULL
suggested	NULL
an	NULL
enrichment	NULL
within	NULL
the	NULL
synovium	NULL
for	NULL
T	NULL
cells	NULL
reac-	NULL
tive	NULL
against	NULL
BZLF1	NULL
in	NULL
patient	NULL
19	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Significant	NULL
TNF	NULL
A	NULL
T	NULL
call	NULL
,	NULL
HLA-	NULL
cDNA	NULL
A14.7	NULL
B	NULL
``	NULL
4002	NULL
BZLFI	NULL
ATG	NULL
+	NULL
.	NULL

Ava	NULL
I	NULL
a	NULL
||	NULL
-	NULL
100	NULL
bp	NULL
J	NULL
10	NULL
0	NULL
Ro	NULL
-	NULL
so	NULL
ag	NULL
=	NULL
so	NULL
TNF	NULL
release	NULL
(	NULL
pg/ml	NULL
)	NULL
[	NULL
we	NULL
a	NULL
a	NULL
$	NULL
-16caAL	NULL
=+	NULL
RAKFWIOLL	NULL
a	NULL
G	NULL
f	NULL
L	NULL
%	NULL
specific	NULL
lysis	NULL
TNF	NULL
release	NULL
(	NULL
pg/ml	NULL
!	NULL
)	NULL

o	NULL
a	NULL
1	NULL
L	NULL
zou	NULL
Peptide	NULL
concentration	NULL
(	NULL
nM	NULL
)	NULL
1acon	NULL
a	NULL
«	NULL
so	NULL
BMLF1	NULL
A'0201	NULL
B*4002	NULL
Cw*0102	NULL
50	NULL
--	NULL
PBL	NULL
|	NULL
40	NULL
-	NULL
#	NULL
-	NULL
SFL	NULL
-A-	NULL
SML	NULL
30	NULL
20	NULL
a	NULL
|	NULL
E	NULL
io	NULL
D	NULL
.	NULL

e	NULL
0	NULL
a	NULL
3	NULL
G	NULL
5	NULL
3	NULL
4	NULL
5	NULL
3	NULL
4	NULL
5	NULL
9	NULL
10	NULL
10	NULL
10°	NULL
10	NULL
10	NULL
10	NULL
5	NULL
10	NULL
19	NULL
10	NULL
E4	NULL
P	NULL
BZLF1	NULL
W	NULL
Z	NULL
A	NULL
``	NULL
0201	NULL
B+4002	NULL
Cw*0102	NULL
I	NULL
``	NULL
so	NULL
o	NULL
|	NULL
p	NULL
<	NULL
a	NULL
g	NULL
40	NULL
r	NULL
30	NULL
209	NULL
10	NULL
0	NULL
10°	NULL
10	NULL
%	NULL
0	NULL
ro	NULL
'as	NULL
?	NULL

10	NULL
%	NULL
0	NULL
ao	NULL
ao	NULL
?	NULL

10	NULL
%	NULL
ao	NULL
?	NULL

Cell	NULL
number	NULL
Figure	NULL
4	NULL
.	NULL

TNF	NULL
responses	NULL
of	NULL
PBL	NULL
,	NULL
SFL	NULL
,	NULL
and	NULL
SML	NULL
from	NULL
patient	NULL
1	NULL
to	NULL
BMLEF1-	NULL
or	NULL
BZLF1-transfected	NULL
COS	NULL
cells	NULL
.	NULL

Short-term-cultured	NULL
PBL	NULL
,	NULL
SFL	NULL
,	NULL
and	NULL
SML	NULL
were	NULL
incubated	NULL
with	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
1796	NULL
Pru	NULL
©	NULL
ava	NULL
t	NULL
Pso	NULL
|	NULL
Hine	NULL
i	NULL
l	NULL
Peptide	NULL
concentration	NULL
(	NULL
nM	NULL
)	NULL
Fignre	NULL
-	NULL
3	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
BZLF1	NULL
peptide	NULL
recognized	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
clone	NULL
A14.7	NULL
.	NULL

(	NULL
A	NULL
)	NULL
BZLF1	NULL
recogni-tron	NULL
by	NULL
the	NULL
HLA-B*4002-restricted	NULL
T	NULL
cell	NULL
clone	NULL
A14	NULL
7	NULL
.	NULL

TNE	NULL
release	NULL
by	NULL
clone	NULL
A14.7	NULL
was	NULL
measured	NULL
after	NULL
incubation	NULL
with	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
BZLF1	NULL
and	NULL
HLA-B*4002	NULL
cDNA	NULL
or	NULL
with	NULL
each	NULL
of	NULL
these	NULL
cDNA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Mapping	NULL
of	NULL
the	NULL
BZLFI	NULL
sequence	NULL
coding	NULL
for	NULL
the	NULL
antigeme	NULL
pepude	NULL
recognized	NULL
by	NULL
clone	NULL
A14.7	NULL
.	NULL

For	NULL
experimental	NULL
pro-cedures	NULL
,	NULL
see	NULL
Matemals	NULL
and	NULL
Methods	NULL
and	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Induction	NULL
of	NULL
Al4.7	NULL
clone	NULL
autacytotoxicity	NULL
by	NULL
synthetic	NULL
RZLF1	NULL
peptides	NULL
.	NULL

One	NULL
peptide	NULL
(	NULL
SENDRLRLL	NULL
)	NULL
encoded	NULL
by	NULL
the	NULL
90-bp	NULL
Pst	NULL
[	NULL
/Hincl	NULL
!	NULL

fragment	NULL
defined	NULL
in	NULL
B	NULL
and	NULL
containing	NULL
consensus	NULL
binding	NULL
anchor	NULL
residues	NULL
to	NULL
HLA-B*4002	NULL
(	NULL
28	NULL
)	NULL
was	NULL
synthesized	NULL
,	NULL
T	NULL
cell	NULL
clone	NULL
cytotoxicity	NULL
was	NULL
estimated	NULL
after	NULL
incubation	NULL
for	NULL
3	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
the	NULL
above	NULL
peptide	NULL
or	NULL
an	NULL
irrelevant	NULL
one	NULL
{	NULL
RAKFKQLL	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Induction	NULL
of	NULL
Al4.7	NULL
clone	NULL
TNF	NULL
release	NULL
by	NULL
synthetic	NULL
BZLF1	NULL
pepudes	NULL
.	NULL

TNF	NULL
production	NULL
was	NULL
estimated	NULL
after	NULL
a	NULL
3-h	NULL
incubation	NULL
with	NULL
peptide	NULL
SENDRLRLL	NULL
.	NULL

TNF	NULL
+	NULL
release	NULL
Hinc	NULL
A	NULL
ssa	NULL
800	NULL
responses	NULL
to	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
HLA-A*0201	NULL
and	NULL
either	NULL
BMLF1	NULL
or	NULL
BZLF1	NULL
cDNA	NULL
were	NULL
also	NULL
readily	NULL
detected	NULL
within	NULL
short-term-cultured	NULL
synovial	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
4	NULL
out	NULL
of	NULL
9	NULL
HLA-A*02	NULL
patients	NULL
(	NULL
patients	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
left	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similarly	NULL
to	NULL
patient	NULL
1	NULL
,	NULL
an	NULL
enrichment	NULL
for	NULL
HLA-A*02/BMLF1	NULL
reactive	NULL
cells	NULL
within	NULL
the	NULL
joints	NULL
of	NULL
patient	NULL
6	NULL
was	NULL
seen	NULL
when	NULL
comparing	NULL
TNF	NULL
production	NULL
obtained	NULL
with	NULL
PBL	NULL
and	NULL
SFL	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
T	NULL
cells	NULL
reactive	NULL
against	NULL
these	NULL
EBV	NULL
transactivators	NULL
are	NULL
frequently	NULL
expanded	NULL
during	NULL
chronic	NULL
RA	NULL
.	NULL

Evaluation	NULL
of	NULL
Cytolytic	NULL
Activity	NULL
of	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clones	NULL
toward	NULL
BLC	NULL
.	NULL

-	NULL
Because	NULL
BLC	NULL
are	NULL
known	NULL
to	NULL
be	NULL
latently	NULL
infected	NULL
by	NULL
EBV	NULL
,	NULL
the	NULL
recognition	NULL
by	NULL
BLC-reactive	NULL
T	NULL
cells	NULL
of	NULL
BMLF1	NULL
or	NULL
BZLF1	NULL
,	NULL
which	NULL
are	NULL
expressed	NULL
exclusively	NULL
during	NULL
the	NULL
virus	NULL
lytic	NULL
cycle	NULL
,	NULL
was	NULL
rather	NULL
unexpected	NULL
and	NULL
prompted	NULL
us	NULL
to	NULL
analyze	NULL
further	NULL
the	NULL
functional	NULL
behavior	NULL
of	NULL
these	NULL
T	NULL
cells	NULL
toward	NULL
BLC	NULL
.	NULL

Although	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
strongly	NULL
pro	NULL
BMLFL	NULL
cDNA	NULL
together	NULL
with	NULL
HLA-A*0201	NULL
lef	NULL
)	NULL
,	NULL
B	NULL
``	NULL
4002	NULL
{	NULL
upper	NULL
middle	NULL
)	NULL
,	NULL
or	NULL
Cw*0102	NULL
(	NULL
upper	NULL
right	NULL
)	NULL
,	NULL
or	NULL
BZLFL	NULL
cDNA	NULL
together	NULL
with	NULL
HLA-A*0201	NULL
(	NULL
fower	NULL
lef	NULL
)	NULL
,	NULL
B*4002	NULL
{	NULL
lower	NULL
muddle	NULL
)	NULL
,	NULL
or	NULL
Cw*0102	NULL
DNA	NULL
(	NULL
lower	NULL
right	NULL
)	NULL
.	NULL

Lymphocytes	NULL
were	NULL
added	NULL
at	NULL
three	NULL
concentrations	NULL
to	NULL
COS	NULL
cells	NULL
1	NULL
d	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
TNF	NULL
release	NULL
was	NULL
measured	NULL
1	NULL
d	NULL
later	NULL
.	NULL

Specific	NULL
TNF	NULL
release	NULL
was	NULL
calculated	NULL
by	NULL
subtracung	NULL
values	NULL
obtained	NULL
with	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
BZLFI	NULL
or	NULL
BMLFI1	NULL
and	NULL
an	NULL
irrelevant	NULL
HLA	NULL
DNA	NULL
{	NULL
A*0101	NULL
}	NULL
from	NULL
those	NULL
obtauned	NULL
under	NULL
the	NULL
above	NULL
conditions	NULL
Note	NULL
that	NULL
dominant	NULL
responses	NULL
to	NULL
BMLFL/A*0201	NULL
and	NULL
BZLF1/B*4002	NULL
were	NULL
observed	NULL
with	NULL
hoth	NULL
SPL	NULL
and	NULL
SML	NULL
recovered	NULL
27	NULL
mo	NULL
later	NULL
.	NULL

There	NULL
was	NULL
at	NULL
least	NULL
a	NULL
100-fold	NULL
difference	NULL
{	NULL
on	NULL
a	NULL
per	NULL
cell	NULL
basis	NULL
}	NULL
between	NULL
the	NULL
amounts	NULL
of	NULL
TNF	NULL
released	NULL
by	NULL
SFL	NULL
versus	NULL
PBL	NULL
after	NULL
exposure	NULL
to	NULL
BMLFL/A*0201-	NULL
and	NULL
BZLF1/B*4002-transfected	NULL
COS	NULL
cells	NULL
.	NULL

Weak	NULL
but	NULL
significant	NULL
responses	NULL
to	NULL
BMLF1/B*4002	NULL
(	NULL
upper	NULL
middle	NULL
)	NULL
,	NULL
BZLFL/A*0201	NULL
(	NULL
lower	NULL
lef	NULL
)	NULL
,	NULL
and	NULL
BZLFL/CW*	NULL
``	NULL
0102	NULL
(	NULL
lower	NULL
right	NULL
)	NULL
were	NULL
obtaned	NULL
with	NULL
SFL	NULL
and/or	NULL
SML	NULL
.	NULL

Anti-EBV	NULL
T	NULL
Cell	NULL
Responses	NULL
in	NULL
Rheumatoid	NULL
Arthritis	NULL
Table	NULL
3	NULL
.	NULL

-	NULL
TNF	NULL
Responses	NULL
of	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clones	NULL
from	NULL
Patient	NULL
19	NULL
to	NULL
or	NULL
BZLF1	NULL
transfected	NULL
COS	NULL
Cells	NULL
Table	NULL
4	NULL
.	NULL

-	NULL
Cytolytic	NULL
Activity	NULL
of	NULL
Synovial	NULL
T	NULL
Cell	NULL
Clones	NULL
from	NULL
Patient	NULL
1	NULL
toward	NULL
BLC	NULL
Triggering	NULL
their	NULL
Proliferation	NULL
TNF	NULL
release	NULL
Cytotoxicity	NULL
B'*3501	NULL
BLC	NULL
BLC	NULL
+	NULL
lectin	NULL
--	NULL
-	NULL
--	NULL
«	NULL
--	NULL
-	NULL
--	NULL
-	NULL
-	NULL
a	NULL
--	NULL
-	NULL
Specific	NULL
T	NULL
cell	NULL
clone	NULL
(	NULL
-	NULL
)	NULL
BMLE1	NULL
BZLFI	NULL
T	NULL
cell	NULL
clone	NULL
20:1	NULL
5:1	NULL
20:1	NULL
5:1	NULL
proliferation	NULL
pg/ml	NULL
A2.3	NULL
3	NULL
1	NULL
67	NULL
54	NULL
26	NULL
833	NULL
B2	NULL
--	NULL
-	NULL
26.5	NULL
A2.10	NULL
2	NULL
0	NULL
68	NULL
55	NULL
12	NULL
457	NULL
B3	NULL
~	NULL
-	NULL
32.3	NULL
A2.19	NULL
6	NULL
6	NULL
70	NULL
72	NULL
48	NULL
129	NULL
B4	NULL
-	NULL
-	NULL
27.4	NULL
A14.7	NULL
7	NULL
6	NULL
88	NULL
70	NULL
70	NULL
374	NULL
A17.10	NULL
4	NULL
4	NULL
46	NULL
35	NULL
66	NULL
877	NULL
TNF	NULL
production	NULL
by	NULL
T	NULL
cell	NULL
clones	NULL
was	NULL
estimated	NULL
after	NULL
incubation	NULL
with	NULL
AlZ.11	NULL
3	NULL
3	NULL
74	NULL
68	NULL
7	NULL
795	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
HLA-B	NULL
``	NULL
3501	NULL
cDNA	NULL
and	NULL
either	NULL
BMLFI1	NULL
or	NULL
A22.19	NULL
5	NULL
4	NULL
81	NULL
83	NULL
61	NULL
656	NULL
BZLFI	NULL
cDNAs	NULL
.	NULL

-	NULL
,	NULL
TNF	NULL
secretion	NULL
<	NULL
1.0	NULL
pg/ml	NULL
A22.38	NULL
10	NULL
i	NULL
79	NULL
61	NULL
78	NULL
196	NULL
liferated	NULL
when	NULL
exposed	NULL
to	NULL
BLC	NULL
expressing	NULL
the	NULL
appropriate	NULL
HLA	NULL
allele	NULL
(	NULL
Table	NULL
4	NULL
;	NULL
and	NULL
reference	NULL
20	NULL
)	NULL
,	NULL
none	NULL
of	NULL
them	NULL
were	NULL
able	NULL
to	NULL
kill	NULL
to	NULL
detectable	NULL
levels	NULL
BLC	NULL
which	NULL
otherwise	NULL
triggered	NULL
their	NULL
proliferation	NULL
(	NULL
Table	NULL
4	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
could	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
a	NULL
lack	NULL
of	NULL
lytic	NULL
potential	NULL
because	NULL
(	NULL
a	NULL
)	NULL
these	NULL
clones	NULL
efficiently	NULL
lysed	NULL
BLC	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
lectin	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
,	NULL
and	NULL
(	NULL
b	NULL
)	NULL
addition	NULL
of	NULL
appropriate	NULL
synthetic	NULL
peptides	NULL
to	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
resulted	NULL
in	NULL
efficient	NULL
peptide	NULL
self	NULL
presentation	NULL
and	NULL
autocytotoxicity	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Actually	NULL
,	NULL
this	NULL
peculiar	NULL
behavior	NULL
is	NULL
most	NULL
probably	NULL
explained	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
clone	NULL
's	NULL
fine	NULL
specificity	NULL
.	NULL

Indeed	NULL
,	NULL
although	NULL
BLC	NULL
are	NULL
known	NULL
to	NULL
express	NULL
predominantly	NULL
EBV	NULL
latent	NULL
proteins	NULL
,	NULL
rare	NULL
cells	NULL
supporting	NULL
a	NULL
fully	NULL
productive	NULL
EBV	NULL
infection	NULL
have	NULL
BMLF1/	NULL
A	NULL
'	NULL
0201	NULL
BZLF1/	NULL
B*	NULL
3501	NULL
a	NULL
-m	NULL
0	NULL
E	NULL
'	NULL
a	NULL
°	NULL
a	NULL
&	NULL
-*-	NULL
#	NULL
3	NULL
a	NULL
5	NULL
5	NULL
5	NULL
4	NULL
a	NULL
®	NULL
i	NULL
2	NULL
a	NULL
E	NULL
>	NULL
a	NULL
8	NULL
e	NULL
I	NULL
1	NULL
1	NULL
G.	NULL
A	NULL
a	NULL
o	NULL
PBL	NULL
SFL	NULL
PBL	NULL
SFL	NULL
Figure	NULL
5.	NULL
.	NULL

TNF	NULL
responses	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
denved	NULL
from	NULL
HLA-B*35*	NULL
and	NULL
HLA-A	NULL
``	NULL
02*	NULL
chrome	NULL
RA	NULL
patients	NULL
to	NULL
BMLFL-	NULL
or	NULL
BZLF1-transfected	NULL
COS	NULL
cells	NULL
105	NULL
short-term-cultured	NULL
synovial	NULL
T	NULL
cells	NULL
and	NULL
PBL	NULL
derived	NULL
from	NULL
nine	NULL
HLA-A2+*	NULL
RA	NULL
patients	NULL
and	NULL
one	NULL
HLA-B*35*	NULL
patient	NULL
were	NULL
incubated	NULL
.	NULL

with	NULL
COS	NULL
cells	NULL
transfected	NULL
with	NULL
HLA-¥	NULL
``	NULL
0201	NULL
and	NULL
BMLFL	NULL
or	NULL
with	NULL
HLA-B*3501	NULL
and	NULL
BZLF1	NULL
DNA	NULL
,	NULL
respectively	NULL
.	NULL

Specific	NULL
TNF	NULL
release	NULL
was	NULL
calculated	NULL
by	NULL
subtracting	NULL
the	NULL
amounts	NULL
of	NULL
TNF	NULL
secreted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
COS	NULL
cells	NULL
transfected	NULL
.	NULL

with	NULL
an	NULL
irrelevant	NULL
HLA	NULL
DNA	NULL
(	NULL
HLA-A	NULL
``	NULL
0301	NULL
)	NULL
and	NULL
either	NULL
BZLF1	NULL
or	NULL
BMLM	NULL
from	NULL
those	NULL
obtained	NULL
with	NULL
the	NULL
restricting	NULL
HLA	NULL
DNA	NULL
.	NULL

Significant	NULL
responses	NULL
were	NULL
observed	NULL
in	NULL
5	NULL
patients	NULL
{	NULL
patients	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
19	NULL
)	NULL
,	NULL
Shown	NULL
are	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
three	NULL
HLA-A*02	NULL
patents	NULL
(	NULL
patients	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
{	NULL
le	NULL
)	NULL
and	NULL
with	NULL
the	NULL
HLA-B*35	NULL
patient	NULL
(	NULL
patient	NULL
19	NULL
)	NULL
(	NULL
right	NULL
)	NULL
.	NULL

For	NULL
patient	NULL
3	NULL
,	NULL
results	NULL
obtained	NULL
with	NULL
PBL	NULL
were	NULL
not	NULL
interpretable	NULL
because	NULL
of	NULL
a	NULL
lugh	NULL
spontaneous	NULL
TNF	NULL
release	NULL
1797	NULL
Scoter	NULL
et	NULL
al	NULL
.	NULL

Cytotoxic	NULL
activity	NULL
of	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
toward	NULL
autologous	NULL
BLC	NULL
(	NULL
no	NULL
.	NULL

1	NULL
)	NULL
was	NULL
assessed	NULL
at	NULL
20:1	NULL
and	NULL
5:1	NULL
E/T	NULL
ratios	NULL
.	NULL

T	NULL
cell	NULL
lytic	NULL
potential	NULL
was	NULL
calculated	NULL
by	NULL
estimating	NULL
target	NULL
killing	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
purified	NULL
PHA	NULL
(	NULL
leucoagglutimn	NULL
)	NULL
(	NULL
0.5	NULL
pg/ml	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
specific	NULL
lysis	NULL
.	NULL

Tritated	NULL
thymudine	NULL
uptake	NULL
of	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
was	NULL
estimated	NULL
after	NULL
a	NULL
2-d	NULL
coculture	NULL
with	NULL
irradiated	NULL
BLC	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
{	NULL
cpm	NULL
of	NULL
'T	NULL
cells	NULL
+	NULL
BLC	NULL
)	NULL
~	NULL
(	NULL
cpm	NULL
of	NULL
T	NULL
cells	NULL
+	NULL
cpm	NULL
of	NULL
BLC	NULL
alone	NULL
)	NULL
.	NULL

Values	NULL
correspond	NULL
to	NULL
means	NULL
of	NULL
duplicate	NULL
counts	NULL
(	NULL
for	NULL
cytotoxicity	NULL
assays	NULL
)	NULL
or	NULL
triplicate	NULL
counts	NULL
(	NULL
for	NULL
proliferation	NULL
assays	NULL
)	NULL
.	NULL

been	NULL
detected	NULL
in	NULL
most	NULL
BLC	NULL
lines	NULL
studied	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Such	NULL
cells	NULL
could	NULL
efficiently	NULL
trigger	NULL
proliferation	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
lytic	NULL
proteins	NULL
,	NULL
although	NULL
their	NULL
lysis	NULL
by	NULL
the	NULL
corresponding	NULL
CTL	NULL
might	NULL
not	NULL
be	NULL
detectable	NULL
in	NULL
standard	NULL
cytotox-	NULL
icity	NULL
assays	NULL
.	NULL

Discussion	NULL
We	NULL
study	NULL
here	NULL
the	NULL
fine	NULL
specificity	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
several	NULL
chronic	NULL
RA	NULL
patients	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
in	NULL
two	NULL
patients	NULL
,	NULL
a	NULL
large	NULL
fraction	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
derived	NULL
from	NULL
synovial	NULL
fluid	NULL
and	NULL
synovial	NULL
membranes	NULL
of	NULL
inflamed	NULL
joints	NULL
reacts	NULL
against	NULL
two	NULL
EBV	NULL
transactivators	NULL
,	NULL
BMLFIL	NULL
and	NULL
BZLF1	NULL
.	NULL

Moreover	NULL
,	NULL
responses	NULL
against	NULL
these	NULL
EBV	NULL
proteins	NULL
were	NULL
evidenced	NULL
within	NULL
short-term-cultured	NULL
synovial	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
several	NULL
other	NULL
RA	NULL
patients	NULL
.	NULL

These	NULL
observations	NULL
raise	NULL
questions	NULL
regarding	NULL
(	NULL
a	NULL
)	NULL
the	NULL
mechanisms	NULL
governing	NULL
T	NULL
cell	NULL
recrutment	NULL
to	NULL
the	NULL
synovium	NULL
during	NULL
chronic	NULL
RA	NULL
,	NULL
(	NULL
b	NULL
)	NULL
the	NULL
implication	NULL
of	NULL
EBV	NULL
in	NULL
chronic	NULL
RA	NULL
pathogenesis	NULL
and	NULL
the	NULL
possible	NULL
pathogenic	NULL
role	NULL
of	NULL
EBV	NULL
tive	NULL
T	NULL
cells	NULL
,	NULL
(	NULL
c	NULL
)	NULL
the	NULL
possible	NULL
dominance	NULL
of	NULL
anti-EBV	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
RA	NULL
patients	NULL
toward	NULL
a	NULL
specific	NULL
set	NULL
of	NULL
proteins	NULL
,	NULL
and	NULL
(	NULL
d	NULL
)	NULL
the	NULL
general	NULL
significance	NULL
and	NULL
consequences	NULL
of	NULL
EBV	NULL
transactivator	NULL
recognition	NULL
by	NULL
T	NULL
cells	NULL
.	NULL

Regarding	NULL
the	NULL
first	NULL
issue	NULL
,	NULL
it	NULL
has	NULL
been	NULL
widely	NULL
accepted	NULL
that	NULL
synovium	NULL
infiltration	NULL
by	NULL
T	NULL
cells	NULL
in	NULL
chronic	NULL
RA	NULL
results	NULL
from	NULL
nonspecific	NULL
trapping	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
c.g	NULL
.	NULL

,	NULL
in	NULL
response	NULL
to	NULL
chemotactic	NULL
factors	NULL
released	NULL
during	NULL
the	NULL
inflammatory	NULL
reaction	NULL
(	NULL
19	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
a	NULL
large	NULL
fraction	NULL
of	NULL
synovial	NULL
T	NULL
cells	NULL
from	NULL
two	NULL
chronic	NULL
RA	NULL
patients	NULL
recognizes	NULL
a	NULL
restricted	NULL
set	NULL
of	NULL
EBV	NULL
antigens	NULL
,	NULL
thus	NULL
demonstrating	NULL
that	NULL
at	NULL
least	NULL
in	NULL
some	NULL
patients	NULL
,	NULL
T	NULL
cell	NULL
recruitment	NULL
to	NULL
the	NULL
synovium	NULL
is	NULL
an	NULL
active	NULL
Ag-driven	NULL
process	NULL
.	NULL

Although	NULL
conflicting	NULL
results	NULL
have	NULL
been	NULL
obtained	NULL
regarding	NULL
the	NULL
presence	NULL
of	NULL
absence	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
in	NULL
synovia	NULL
(	NULL
32-34	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
EBV-reactive	NULL
T	NULL
cells	NULL
are	NULL
expanded	NULL
locally	NULL
after	NULL
recognition	NULL
of	NULL
EBV-infected	NULL
cells	NULL
within	NULL
the	NULL
joint	NULL
.	NULL

Alternatively	NULL
,	NULL
EBV	NULL
could	NULL
trigger	NULL
cross-reactive	NULL
T	NULL
cell	NULL
responses	NULL
against	NULL
cellular	NULL
proteins	NULL
expressed	NULL
in	NULL
target	NULL
organs	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
several	NULL
reports	NULL
have	NULL
described	NULL
shared	NULL
sequences	NULL
between	NULL
MHC	NULL
alleles	NULL
linked	NULL
to	NULL
increased	NULL
RA	NULL
susceptibility	NULL
and	NULL
EBV	NULL
glyco-proteins	NULL
(	NULL
35-38	NULL
)	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
the	NULL
second	NULL
issue	NULL
,	NULL
implication	NULL
of	NULL
EBV	NULL
in	NULL
RA	NULL
was	NULL
first	NULL
proposed	NULL
several	NULL
years	NULL
ago	NULL
,	NULL
based	NULL
on	NULL
several	NULL
clinical	NULL
studies	NULL
demonstrating	NULL
increased	NULL
EBV	NULL
loads	NULL
and	NULL
anti-EBV	NULL
Ab	NULL
titers	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
RA	NULL
patients	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
.	NULL

However	NULL
,	NULL
since	NULL
no	NULL
evidence	NULL
for	NULL
increased	NULL
anti-EBV	NULL
responses	NULL
in	NULL
RA	NULL
lesions	NULL
was	NULL
provided	NULL
,	NULL
the	NULL
physiopathological	NULL
significance	NULL
of	NULL
these	NULL
findings	NULL
has	NULL
remained	NULL
controversial	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
these	NULL
clinical	NULL
observations	NULL
reflected	NULL
a	NULL
general	NULL
alteration	NULL
of	NULL
immune	NULL
responses	NULL
due	NULL
to	NULL
chronic	NULL
inflammation	NULL
rather	NULL
than	NULL
an	NULL
active	NULL
participation	NULL
of	NULL
EBV	NULL
infection	NULL
in	NULL
RA	NULL
pathogenesis	NULL
could	NULL
not	NULL
be	NULL
ruled	NULL
out	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
our	NULL
demonstration	NULL
that	NULL
EBV-reactive	NULL
T	NULL
cells	NULL
are	NULL
enriched	NULL
within	NULL
the	NULL
joints	NULL
of	NULL
chronic	NULL
RA	NULL
patients	NULL
pro-vides	NULL
,	NULL
for	NULL
the	NULL
first	NULL
ume	NULL
,	NULL
a	NULL
direct	NULL
link	NULL
between	NULL
EBV	NULL
and	NULL
RA	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
these	NULL
patients	NULL
showed	NULL
con-comittantly	NULL
high	NULL
anti-EBV	NULL
Ab	NULL
titers	NULL
suggests	NULL
that	NULL
increased	NULL
anti-EBV	NULL
serological	NULL
responses	NULL
previously	NULL
found	NULL
in	NULL
a	NULL
large	NULL
fraction	NULL
of	NULL
chronic	NULL
RA	NULL
patients	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
is	NULL
associated	NULL
with	NULL
specific	NULL
activation	NULL
of	NULL
EBV-reactive	NULL
T	NULL
cells	NULL
within	NULL
the	NULL
le-sions	NULL
,	NULL
Although	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
EBV-reactive	NULL
T	NULL
cells	NULL
in	NULL
RA	NULL
lesions	NULL
are	NULL
very	NULL
likely	NULL
to	NULL
be	NULL
pathogenic	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
established	NULL
definitively	NULL
whether	NULL
these	NULL
cells	NULL
exert	NULL
barmful	NULL
effects	NULL
,	NULL
for	NULL
example	NULL
,	NULL
through	NULL
direct	NULL
cytotoxicity	NULL
of	NULL
release	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
activating	NULL
T	NULL
cell-independent	NULL
joint	NULL
erosion	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
mediated	NULL
by	NULL
synoviocytes	NULL
)	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
behavior	NULL
of	NULL
these	NULL
cells	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
in	NULL
SCID	NULL
models	NULL
)	NULL
will	NULL
certainly	NULL
help	NULL
resolve	NULL
these	NULL
issues	NULL
.	NULL

Whether	NULL
of	NULL
not	NULL
anti-EBV	NULL
responses	NULL
in	NULL
RA	NULL
are	NULL
directed	NULL
against	NULL
a	NULL
restncted	NULL
set	NULL
of	NULL
antigens	NULL
is	NULL
another	NULL
interesting	NULL
ques-tion	NULL
.	NULL

At	NULL
present	NULL
,	NULL
a	NULL
comparison	NULL
of	NULL
EBV	NULL
responses	NULL
between	NULL
RA	NULL
and	NULL
non-RA	NULL
individuals	NULL
remains	NULL
difficult	NULL
,	NULL
because	NULL
none	NULL
of	NULL
the	NULL
studies	NULL
performed	NULL
to	NULL
date	NULL
have	NULL
really	NULL
addressed	NULL
T	NULL
cell	NULL
responses	NULL
against	NULL
EBV	NULL
lytic	NULL
proteins	NULL
in	NULL
non-RA	NULL
EBV-infected	NULL
individuals	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
some	NULL
BLC-reactive	NULL
synovial	NULL
T	NULL
cell	NULL
clones	NULL
do	NULL
not	NULL
respond	NULL
to	NULL
BMLF1	NULL
or	NULL
BZLF1	NULL
in	NULL
COS	NULL
transfection	NULL
assays	NULL
strongly	NULL
suggests	NULL
recognition	NULL
of	NULL
a	NULL
larger	NULL
set	NULL
of	NULL
EBV	NULL
proteins	NULL
by	NULL
RA	NULL
patient	NULL
,	NULL
derived	NULL
T	NULL
cells	NULL
.	NULL

Despite	NULL
this	NULL
,	NULL
biased	NULL
anti-EBV	NULL
responses	NULL
toward	NULL
proteins	NULL
of	NULL
the	NULL
virus	NULL
replicative	NULL
cycle	NULL
in	NULL
RA	NULL
patients	NULL
is	NULL
strongly	NULL
suggested	NULL
by	NULL
the	NULL
following	NULL
observations	NULL
.	NULL

As	NULL
mentioned	NULL
before	NULL
,	NULL
EBV	NULL
is	NULL
known	NULL
to	NULL
enter	NULL
the	NULL
lytic	NULL
cycle	NULL
only	NULL
in	NULL
a	NULL
minonty	NULL
of	NULL
cells	NULL
in	NULL
BLC	NULL
cultures	NULL
.	NULL

Therefore	NULL
a	NULL
dominant	NULL
response	NULL
against	NULL
proteins	NULL
expressed	NULL
at	NULL
that	NULL
stage	NULL
could	NULL
explain	NULL
both	NULL
the	NULL
decreased	NULL
cytotoxic	NULL
responses	NULL
against	NULL
autologous	NULL
BLC	NULL
frequently	NULL
observed	NULL
in	NULL
RA	NULL
patients	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
and	NULL
our	NULL
inability	NULL
to	NULL
detect	NULL
significant	NULL
killing	NULL
of	NULL
BLC	NULL
by	NULL
synovial	NULL
CTL	NULL
in	NULL
standard	NULL
cytotoxicity	NULL
assays	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
this	NULL
peculiar	NULL
behavior	NULL
could	NULL
also	NULL
explain	NULL
why	NULL
synovial	NULL
CD8+*	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
EBV	NULL
have	NULL
not	NULL
been	NULL
detected	NULL
before	NULL
,	NULL
because	NULL
specificity	NULL
of	NULL
these	NULL
cells	NULL
is	NULL
classically	NULL
established	NULL
through	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

Beyond	NULL
the	NULL
field	NULL
of	NULL
autoimmunity	NULL
,	NULL
these	NULL
observations	NULL
provide	NULL
new	NULL
insights	NULL
into	NULL
the	NULL
fine	NULL
specificity	NULL
of	NULL
the	NULL
anti-EBV	NULL
T	NULL
cell	NULL
response	NULL
and	NULL
the	NULL
immune	NULL
control	NULL
of	NULL
EBV	NULL
reactiva-tion	NULL
,	NULL
because	NULL
they	NULL
provide	NULL
the	NULL
first	NULL
clear-cut	NULL
evidence	NULL
that	NULL
the	NULL
BZLF1	NULL
and	NULL
BMLF1	NULL
EBV	NULL
-transactivating	NULL
proteins	NULL
can	NULL
be	NULL
targets	NULL
for	NULL
CD8¢	NULL
T	NULL
cells	NULL
.	NULL

T	NULL
cell	NULL
recognition	NULL
of	NULL
such	NULL
proteins	NULL
has	NULL
been	NULL
suspected	NULL
in	NULL
several	NULL
EBV	NULL
-linked	NULL
pathological	NULL
situations	NULL
{	NULL
e.g	NULL
.	NULL

,	NULL
acute	NULL
infectious	NULL
mononucleosis	NULL
,	NULL
nasopha-ryngeal	NULL
carcinoma	NULL
,	NULL
EBV	NULL
reactivation	NULL
in	NULL
immunodepressed	NULL
patients	NULL
)	NULL
during	NULL
which	NULL
serological	NULL
Ab	NULL
titers	NULL
against	NULL
product	NULL
and	NULL
other	NULL
early	NULL
antigens	NULL
are	NULL
significantly	NULL
increased	NULL
(	NULL
for	NULL
review	NULL
see	NULL
reference	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
technical	NULL
limitations	NULL
have	NULL
hampered	NULL
direct	NULL
analysis	NULL
of	NULL
T	NULL
cell	NULL
responses	NULL
directed	NULL
against	NULL
EBV	NULL
lytic	NULL
antigens	NULL
.	NULL

The	NULL
physiological	NULL
significance	NULL
of	NULL
BZLF1/BMLF1L	NULL
recognition	NULL
by	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
inferred	NULL
from	NULL
the	NULL
function	NULL
of	NULL
these	NULL
proteins	NULL
during	NULL
virus	NULL
replication	NULL
.	NULL

BZLF1	NULL
is	NULL
the	NULL
first	NULL
gene	NULL
expressed	NULL
during	NULL
the	NULL
immediate	NULL
early	NULL
stage	NULL
of	NULL
the	NULL
EBV	NULL
lytic	NULL
cycle	NULL
,	NULL
and	NULL
it	NULL
is	NULL
thought	NULL
to	NULL
turn	NULL
on	NULL
expression	NULL
of	NULL
many	NULL
other	NULL
immediate	NULL
early	NULL
genes	NULL
(	NULL
43	NULL
)	NULL
.	NULL

BMLF1	NULL
is	NULL
a	NULL
delayed	NULL
immediate	NULL
early	NULL
gene	NULL
with	NULL
promiscuous	NULL
transactivating	NULL
properties	NULL
that	NULL
acts	NULL
syner-gistically	NULL
with	NULL
BMLFL	NULL
and	NULL
another	NULL
EBV	NULL
transactivator	NULL
,	NULL
BRLEF1	NULL
,	NULL
in	NULL
in	NULL
vitro	NULL
assays	NULL
(	NULL
43	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
likely	NULL
that	NULL
T	NULL
cell	NULL
responses	NULL
against	NULL
these	NULL
two	NULL
key	NULL
transactivators	NULL
of	NULL
EBV	NULL
lytic	NULL
infection	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
controlling	NULL
virus	NULL
spreading	NULL
under	NULL
physiological	NULL
and	NULL
pathological	NULL
situations	NULL
.	NULL

With	NULL
the	NULL
recent	NULL
development	NULL
of	NULL
murine	NULL
models	NULL
allowing	NULL
in	NULL
vivo	NULL
analysis	NULL
of	NULL
anti-EBV	NULL
human	NULL
T	NULL
cell	NULL
responses	NULL
(	NULL
44	NULL
)	NULL
,	NULL
this	NULL
hypothesis	NULL
can	NULL
now	NULL
be	NULL
tested	NULL
.	NULL

We	NULL
thank	NULL
R.	NULL
Bataille	NULL
for	NULL
helfpul	NULL
comments	NULL
and	NULL
T.	NULL
Boon	NULL
,	NULL
Dr.	NULL
J.	NULL
Girdlestone	NULL
,	NULL
and	NULL
Dr.	NULL
L.	NULL
Satz	NULL
for	NULL
providing	NULL
the	NULL
HLA-A*0101	NULL
,	NULL
-A*0201	NULL
,	NULL
-A*0301	NULL
,	NULL
-A*2401	NULL
,	NULL
and	NULL
-B*3501	NULL
DNAs	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
la	NULL
Polyarthrite	NULL
,	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
,	NULL
the	NULL
Ministére	NULL
de	NULL
'Education	NULL
Matonale	NULL
,	NULL
de	NULL
Enseignement	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
(	NULL
E.	NULL
Scotet	NULL
)	NULL
,	NULL
the	NULL
Ligne	NULL
Région	NULL
Départementale	NULL
contre	NULL
le	NULL
Cancer	NULL
,	NULL
the	NULL
Centre	NULL
Hospitalier	NULL
Universi-taire	NULL
{	NULL
CHU	NULL
Nantes	NULL
)	NULL
,	NULL
and	NULL
by	NULL
institutional	NULL
grants	NULL
from	NULL
INSERM	NULL
.	NULL

1798	NULL
Anti-EBV	NULL
T	NULL
Cell	NULL
Responses	NULL
in	NULL
Rheumatoid	NULL
Arthritis	NULL
Address	NULL
correspondence	NULL
to	NULL
Marc	NULL
Bonneville	NULL
,	NULL
Inserm	NULL
U211	NULL
,	NULL
Institut	NULL
de	NULL
Biologie	NULL
,	NULL
9	NULL
quai	NULL
Moncousu	NULL
,	NULL
44035	NULL
Nantes	NULL
Cedex	NULL
01	NULL
,	NULL
France	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
7	NULL
June	NULL
1996	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
6	NULL
August	NULL
1996	NULL
.	NULL

References	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Harms	NULL
,	NULL
ED	NULL
.	NULL

1990	NULL
.	NULL

Rheumatoid	NULL
arthritis	NULL
pathophysiology	NULL
and	NULL
implications	NULL
for	NULL
therapy	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

322:1277-1289.	NULL
.	NULL

Van	NULL
Boxel	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
and	NULL
S.A.	NULL
Paget	NULL
.	NULL

1975	NULL
.	NULL

Predominantly	NULL
T-cell	NULL
infiltrate	NULL
in	NULL
rheumatoid	NULL
synovial	NULL
membrane	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
,	NULL
293:517-520.	NULL
.	NULL

McMichael	NULL
,	NULL
AJ	NULL
.	NULL

,	NULL
K.	NULL
Sasazuki	NULL
,	NULL
H.O0	NULL
.	NULL

McDevitt	NULL
,	NULL
and	NULL
R.O	NULL
.	NULL

Payne	NULL
.	NULL

1977	NULL
.	NULL

Increased	NULL
frequency	NULL
of	NULL
HLA-Cw3	NULL
and	NULL
HLA-Dw4	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthwsifis	NULL
Rheum	NULL
.	NULL

20:1037-1042.	NULL
.	NULL

Statiny	NULL
,	NULL
P.	NULL
1978	NULL
.	NULL

Association	NULL
of	NULL
the	NULL
B-cell	NULL
alloantigen	NULL
Drw4	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

298:869-871.	NULL
,	NULL
.	NULL

Legrand	NULL
,	NULL
L.	NULL
,	NULL
G.M	NULL
.	NULL

Lathrop	NULL
,	NULL
A.	NULL
Marcellh-Barge	NULL
,	NULL
A.	NULL
Dryll	NULL
,	NULL
T.	NULL
Bardin	NULL
,	NULL
N.	NULL
Debeyre	NULL
,	NULL
J.C.	NULL
Poiner	NULL
,	NULL
M.	NULL
Schmidt	NULL
,	NULL
A.	NULL
Ryckewaert	NULL
,	NULL
and	NULL
J.	NULL
Dausset	NULL
.	NULL

1984	NULL
.	NULL

HLA-DR	NULL
genotype	NULL
risks	NULL
in	NULL
seropositive	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Aim	NULL
.	NULL

J.	NULL
Hum	NULL
.	NULL

Genet	NULL
.	NULL

36:690-699.	NULL
.	NULL

Zoschke	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
M.	NULL
Segall	NULL
,	NULL
1986	NULL
.	NULL

Dw	NULL
subtypes	NULL
of	NULL
DRA4	NULL
in	NULL
rheumatord	NULL
arthritis	NULL
:	NULL
evidence	NULL
for	NULL
a	NULL
preferential	NULL
association	NULL
with	NULL
Dw4	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

15:118-124.	NULL
.	NULL

Weyand	NULL
,	NULL
CM	NULL
.	NULL

,	NULL
K.C	NULL
.	NULL

Hicock	NULL
,	NULL
D.L	NULL
.	NULL

Conn	NULL
,	NULL
and	NULL
J.J.	NULL
Gorongy	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
influence	NULL
of	NULL
HLA-DRB1	NULL
genes	NULL
on	NULL
disease	NULL
severity	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Asn	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

117:801-806.	NULL
.	NULL

Herzog	NULL
,	NULL
CH	NULL
.	NULL

,	NULL
C.	NULL
Walker	NULL
,	NULL
W.	NULL
Pichler	NULL
,	NULL
A.	NULL
Aeschlimann	NULL
,	NULL
P.	NULL
Wassmer	NULL
,	NULL
H.	NULL
Stockinger	NULL
,	NULL
W.	NULL
Knapp	NULL
,	NULL
P.	NULL
Rueber	NULL
,	NULL
and	NULL
W.	NULL
Muller	NULL
.	NULL

1987	NULL
.	NULL

Monoclonal	NULL
anti-CD4	NULL
in	NULL
arthritis	NULL
.	NULL

Lancet	NULL
.	NULL

2	NULL
:	NULL
1461-1462.	NULL
.	NULL

Yocum	NULL
,	NULL
D.E	NULL
.	NULL

,	NULL
JH	NULL
.	NULL

Klippel	NULL
,	NULL
RL	NULL
.	NULL

Wilder	NULL
,	NULL
NL	NULL
.	NULL

Gerber	NULL
,	NULL
H.A	NULL
.	NULL

Austin	NULL
,	NULL
S.M	NULL
.	NULL

Wahl	NULL
,	NULL
L.	NULL
Lesko	NULL
,	NULL
J.R.	NULL
Minor	NULL
,	NULL
H.G	NULL
.	NULL

Preuss	NULL
,	NULL
and	NULL
C.	NULL
Yarboro	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
in	NULL
severe	NULL
treatment	NULL
refractory	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

A	NULL
randomized	NULL
study	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
,	NULL
Med	NULL
.	NULL

109:863-869	NULL
.	NULL

Londei	NULL
,	NULL
M.	NULL
,	NULL
GC.M	NULL
.	NULL

Savill	NULL
,	NULL
A.	NULL
Verhoef	NULL
,	NULL
F.	NULL
Brennan	NULL
,	NULL
Z.A	NULL
.	NULL

Leech	NULL
,	NULL
V.	NULL
Duance	NULL
,	NULL
KR.N	NULL
.	NULL

Maini	NULL
,	NULL
and	NULL
M.	NULL
Feldmann	NULL
,	NULL
1989	NULL
,	NULL
Persistence	NULL
of	NULL
collagen	NULL
type	NULL
I-specific	NULL
T	NULL
cell	NULL
clones	NULL
in	NULL
the	NULL
synovial	NULL
membrane	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:636-640	NULL
.	NULL

Trentham	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
K.E	NULL
.	NULL

Dynesius	NULL
,	NULL
R.	NULL
Rocklin	NULL
,	NULL
and	NULL
JR.	NULL
David	NULL
,	NULL
1976	NULL
,	NULL
Cellular	NULL
sensitivity	NULL
to	NULL
collagen	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

229:327-332	NULL
.	NULL

Holoshitz	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Klaiman	NULL
,	NULL
I.	NULL
Drucker	NULL
,	NULL
Z.	NULL
Lapidot	NULL
,	NULL
A.	NULL
Yaretzky	NULL
,	NULL
A.	NULL
Frenkel	NULL
,	NULL
W.	NULL
van	NULL
Eden	NULL
,	NULL
and	NULL
LR	NULL
.	NULL

Cohen	NULL
.	NULL

1986	NULL
.	NULL

T	NULL
lymphocytes	NULL
of	NULL
rheumatord	NULL
arthrius	NULL
pavients	NULL
show	NULL
augmented	NULL
reactivity	NULL
to	NULL
a	NULL
fraction	NULL
of	NULL
mycobacteria	NULL
cross-reactive	NULL
with	NULL
carti-lage	NULL
.	NULL

Lancet	NULL
,	NULL
2:305-309	NULL
%	NULL
.	NULL

Res	NULL
,	NULL
PCM	NULL
.	NULL

,	NULL
C.G	NULL
.	NULL

Shaar	NULL
,	NULL
F.C	NULL
.	NULL

Breedveld	NULL
,	NULL
W.	NULL
van	NULL
Eden	NULL
,	NULL
J.D.A	NULL
van	NULL
Embden	NULL
,	NULL
LR	NULL
.	NULL

Cohen	NULL
,	NULL
and	NULL
RRP	NULL
.	NULL

de	NULL
Vrics	NULL
.	NULL

1988	NULL
.	NULL

Synovial	NULL
fluid	NULL
T	NULL
cell	NULL
reactivity	NULL
against	NULL
65	NULL
kD	NULL
heat	NULL
shock	NULL
pro-tem	NULL
of	NULL
mycobactena	NULL
in	NULL
early	NULL
chronic	NULL
arthritis	NULL
.	NULL

Lancet	NULL
.	NULL

2:478-480	NULL
.	NULL

Gaston	NULL
,	NULL
JSH	NULL
,	NULL
P.F	NULL
.	NULL

Life	NULL
,	NULL
P.J	NULL
.	NULL

Jenner	NULL
,	NULL
M.J.	NULL
Colston	NULL
,	NULL
and	NULL
PA.	NULL
Bacon	NULL
.	NULL

1990	NULL
.	NULL

Recognition	NULL
of	NULL
a	NULL
mycobacteria-specific	NULL
epitope	NULL
in	NULL
the	NULL
65-kD	NULL
heat-shock	NULL
protein	NULL
by	NULL
synovial	NULL
fluid-derived	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171:831-841	NULL
.	NULL

Fischer	NULL
,	NULL
HP	NULL
.	NULL

,	NULL
C.E.M	NULL
.	NULL

Sharrock	NULL
,	NULL
MJ	NULL
.	NULL

Colston	NULL
,	NULL
and	NULL
G.S	NULL
.	NULL

Panayi	NULL
.	NULL

1991	NULL
,	NULL
Linuiting	NULL
dilution	NULL
analysis	NULL
of	NULL
proliferative	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
mycobacterial	NULL
65	NULL
kDa	NULL
heat-shock	NULL
protein	NULL
fails	NULL
to	NULL
show	NULL
significant	NULL
frequency	NULL
differences	NULL
between	NULL
synovial	NULL
fluid	NULL
1799	NULL
Scotet	NULL
et	NULL
al	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
,	NULL
21	NULL
.	NULL

22	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
,	NULL
29.	NULL
and	NULL
peripheral	NULL
blood	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21:29-37	NULL
.	NULL

Lotz	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
J.	NULL
Roudier	NULL
,	NULL
1992	NULL
.	NULL

Epsteim-Barr	NULL
virus	NULL
and	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Is	NULL
Rheumatoid	NULL
Arthritis	NULL
.	NULL

E.	NULL
Smolen	NULL
,	NULL
J.	NULL
Kalden	NULL
,	NULL
and	NULL
R.N	NULL
.	NULL

Maini	NULL
,	NULL
editors	NULL
.	NULL

Springer	NULL
Verlag	NULL
,	NULL
Berlin	NULL
.	NULL

257-280	NULL
.	NULL

Fox	NULL
,	NULL
R.1	NULL
.	NULL

,	NULL
M.	NULL
Luppi	NULL
,	NULL
P.	NULL
Pisa	NULL
,	NULL
and	NULL
HA	NULL
.	NULL

Kang	NULL
.	NULL

1992	NULL
.	NULL

Potential	NULL
role	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
Sjégren	NULL
's	NULL
syndrome	NULL
and	NULL
theuma-toid	NULL
arthritis	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

19	NULL
:	NULL
18-24	NULL
.	NULL

Struyk	NULL
,	NULL
L.	NULL
,	NULL
G.E	NULL
.	NULL

Hawes	NULL
,	NULL
MK	NULL
.	NULL

Chatila	NULL
,	NULL
F.C	NULL
.	NULL

Breedveld	NULL
,	NULL
J.T	NULL
.	NULL

Kumnick	NULL
,	NULL
and	NULL
P.J	NULL
.	NULL

van	NULL
den	NULL
Elsen	NULL
,	NULL
1995	NULL
.	NULL

T	NULL
cell	NULL
receptors	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

38:577-589	NULL
.	NULL

Koopman	NULL
,	NULL
WJ	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
future	NULL
of	NULL
bhologics	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
rheumatoid	NULL
arthnitis	NULL
.	NULL

Semin	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

23	NULL
%	NULL
:50-58	NULL
.	NULL

David-Ameline	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Lun	NULL
,	NULL
F.	NULL
Davodeau	NULL
,	NULL
M.A	NULL
.	NULL

Peyrat	NULL
,	NULL
J.M	NULL
.	NULL

Berthelot	NULL
,	NULL
G.	NULL
Semana	NULL
,	NULL
C.	NULL
Pannetier	NULL
,	NULL
J.	NULL
Gaschet	NULL
,	NULL
H.	NULL
Yié	NULL
,	NULL
J	NULL
.	NULL

Even	NULL
,	NULL
and	NULL
M.	NULL
Bonneville	NULL
.	NULL

1996	NULL
.	NULL

Selection	NULL
of	NULL
T	NULL
cells	NULL
reactive	NULL
against	NULL
autologous	NULL
B	NULL
lymphoblastoid	NULL
cells	NULL
during	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

In	NULL
press	NULL
.	NULL

Arnett	NULL
,	NULL
F.C	NULL
.	NULL

,	NULL
$	NULL
.M	NULL
.	NULL

Edworthy	NULL
,	NULL
D.A	NULL
.	NULL

Bloch	NULL
,	NULL
DJ	NULL
.	NULL

McShane	NULL
,	NULL
J.F	NULL
.	NULL

Fries	NULL
,	NULL
N.S	NULL
.	NULL

Cooper	NULL
,	NULL
LA	NULL
.	NULL

Healey	NULL
,	NULL
SR.	NULL
Kaplan	NULL
,	NULL
MM	NULL
.	NULL

Li-ang	NULL
,	NULL
H.S	NULL
.	NULL

Luthra	NULL
ct	NULL
al	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
American	NULL
Rheumatism	NULL
Association	NULL
1987	NULL
revised	NULL
critema	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

31:315-324	NULL
.	NULL

Vié	NULL
,	NULL
H.	NULL
,	NULL
S.	NULL
Chevalier	NULL
,	NULL
R.	NULL
Garand	NULL
,	NULL
J.P.	NULL
Moisan	NULL
,	NULL
V.	NULL
Praloran	NULL
,	NULL
M.C	NULL
.	NULL

Dewilder	NULL
,	NULL
J.F	NULL
.	NULL

Moreau	NULL
,	NULL
and	NULL
J.P.	NULL
Soutilliou	NULL
.	NULL

1989	NULL
.	NULL

Clonal	NULL
expansion	NULL
of	NULL
lymphocytes	NULL
bearing	NULL
the	NULL
gamma/delta	NULL
receptor	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
a	NULL
large	NULL
granular	NULL
lymphocyte	NULL
disorder	NULL
.	NULL

Blood	NULL
.	NULL

74285-2092.	NULL
.	NULL

Bnchard	NULL
,	NULL
V.	NULL
,	NULL
A.	NULL
van	NULL
Pel	NULL
,	NULL
T.	NULL
Woilfel	NULL
,	NULL
C.	NULL
Walfcl	NULL
,	NULL
E.	NULL
De	NULL
Plaen	NULL
,	NULL
B.	NULL
Lethé	NULL
,	NULL
P.	NULL
Coulie	NULL
,	NULL
and	NULL
T.	NULL
Boon	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
tyrosinase	NULL
gene	NULL
codes	NULL
for	NULL
an	NULL
antigen	NULL
recognized	NULL
by	NULL
autologous	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
on	NULL
HLA-AZ3	NULL
melanomas	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:489-495	NULL
.	NULL

Seed	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
A.	NULL
Aruffo	NULL
.	NULL

1987	NULL
.	NULL

Molecular	NULL
clomng	NULL
of	NULL
the	NULL
CD2	NULL
antigen	NULL
,	NULL
the	NULL
T	NULL
cell	NULL
erythrocyte	NULL
receptor	NULL
,	NULL
by	NULL
a	NULL
rapid	NULL
immu-noselection	NULL
procedure	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sai	NULL
.	NULL

USA	NULL
.	NULL

84:3365-3369	NULL
.	NULL

Espevik	NULL
.	NULL

T.	NULL
,	NULL
and	NULL
J.	NULL
Nissen-Meyer	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
highly	NULL
sensative	NULL
cell	NULL
line	NULL
,	NULL
WEHI	NULL
164	NULL
clone	NULL
13	NULL
,	NULL
for	NULL
measuring	NULL
cytotoxic	NULL
fac-tor/tumor	NULL
necrosis	NULL
factor	NULL
from	NULL
human	NULL
monocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
.	NULL

95:99-105	NULL
.	NULL

Wong	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
and	NULL
A.J	NULL
.	NULL

Levine	NULL
.	NULL

1986	NULL
.	NULL

Identification	NULL
and	NULL
mapping	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
antigens	NULL
and	NULL
demonstration	NULL
of	NULL
a	NULL
viral	NULL
gene	NULL
activator	NULL
that	NULL
functions	NULL
in	NULL
frans	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

60	NULL
:	NULL
149-156	NULL
.	NULL

Wong	NULL
.	NULL

KM	NULL
.	NULL

,	NULL
and	NULL
A.J	NULL
.	NULL

Levine	NULL
.	NULL

1989	NULL
.	NULL

Characterization	NULL
of	NULL
proteins	NULL
encoded	NULL
by	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
gene	NULL
BMLF1	NULL
.	NULL

Virology	NULL
.	NULL

16801-1111	NULL
.	NULL

Rammensee	NULL
,	NULL
H.G	NULL
.	NULL

,	NULL
T.	NULL
Fede	NULL
,	NULL
and	NULL
I.	NULL
Stevanovic	NULL
.	NULL

1995	NULL
.	NULL

MHC	NULL
ligands	NULL
and	NULL
pepudes	NULL
:	NULL
first	NULL
listing	NULL
.	NULL

41	NULL
:	NULL
178-228	NULL
.	NULL

Chevalier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
{	NULL
EBV	NULL
)	NULL
-encoded	NULL
trans-acting	NULL
factors	NULL
,	NULL
EB1	NULL
and	NULL
EB2	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
EBV	NULL
early	NULL
promoter	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

37	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
,	NULL
Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

5:3243-3249	NULL
,	NULL
Ruickinson	NULL
,	NULL
A.B	NULL
.	NULL

,	NULL
and	NULL
E.	NULL
Kieff	NULL
1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
.	NULL

In	NULL
Fields	NULL
Virology	NULL
.	NULL

BN	NULL
.	NULL

Fields	NULL
,	NULL
D.M	NULL
.	NULL

Knipe	NULL
,	NULL
P.M.	NULL
Howley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
editors	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA.	NULL
2397-2446	NULL
.	NULL

Firestein	NULL
,	NULL
G.S	NULL
.	NULL

,	NULL
and	NULL
N.J.	NULL
Zvaifler	NULL
.	NULL

1990	NULL
.	NULL

How	NULL
important	NULL
are	NULL
T	NULL
cells	NULL
in	NULL
chronic	NULL
rheumatord	NULL
arthntis	NULL
?	NULL

Artivitis	NULL
Rheum	NULL
.	NULL

33	NULL
:	NULL
768-773.	NULL
.	NULL

Zhang	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Nikkan	NULL
,	NULL
and	NULL
M.	NULL
Skurnik	NULL
.	NULL

1993	NULL
.	NULL

Detection	NULL
of	NULL
herpes	NULL
viruses	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
in	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
rheumatord	NULL
arthritis	NULL
,	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

36	NULL
:	NULL
1080-1086.	NULL
.	NULL

Brousset	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Cauher	NULL
,	NULL
A.	NULL
Cantagrel	NULL
,	NULL
C.	NULL
Dromer	NULL
,	NULL
B.	NULL
Maziéres	NULL
,	NULL
and	NULL
G.	NULL
Delsol	NULL
.	NULL

1993	NULL
.	NULL

Absence	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
carrying	NULL
cells	NULL
in	NULL
synovial	NULL
membranes	NULL
and	NULL
subcutaneous	NULL
nodules	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthnus	NULL
.	NULL

Ana	NULL
.	NULL

Rheum	NULL
.	NULL

Dis	NULL
.	NULL

52:608-609	NULL
.	NULL

Newkirk	NULL
,	NULL
MM	NULL
.	NULL

,	NULL
K.N	NULL
.	NULL

Watanabe	NULL
Duffy	NULL
,	NULL
J.	NULL
Leclerc	NULL
,	NULL
N.	NULL
Lam-bert	NULL
,	NULL
and	NULL
J.B.	NULL
Shiroky	NULL
.	NULL

1994	NULL
.	NULL

Detection	NULL
of	NULL
cytomegalovitus	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
Herpes	NULL
virus-6	NULL
in	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
with	NULL
or	NULL
without	NULL
Sjégren	NULL
's	NULL
syndrome	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

33:317-322	NULL
.	NULL

Venables	NULL
,	NULL
P.JJ.W	NULL
,	NULL
1988	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
infection	NULL
and	NULL
au-toimmunity	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Ang	NULL
.	NULL

Rheum	NULL
.	NULL

Dis	NULL
.	NULL

47	NULL
:	NULL
265-269.	NULL
.	NULL

Rhodes	NULL
,	NULL
G.	NULL
,	NULL
H.	NULL
Rumpold	NULL
,	NULL
P.	NULL
Kurki	NULL
,	NULL
K.M	NULL
.	NULL

Patrick	NULL
,	NULL
D.A	NULL
.	NULL

Carson	NULL
,	NULL
and	NULL
JH	NULL
.	NULL

Vaughan	NULL
.	NULL

1987	NULL
.	NULL

Autoantibodies	NULL
in	NULL
infec-tous	NULL
mononucleosis	NULL
have	NULL
specificity	NULL
for	NULL
the	NULL
glycine-alanine	NULL
repeating	NULL
region	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165:1026-1040	NULL
.	NULL

Fox	NULL
,	NULL
RL	NULL
.	NULL

,	NULL
R.	NULL
Sportsman	NULL
,	NULL
G.H	NULL
.	NULL

Rhodes	NULL
,	NULL
J.	NULL
Luke	NULL
,	NULL
G.	NULL
Pearson	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

Vaughan	NULL
,	NULL
1986	NULL
.	NULL

Rheumatord	NULL
arthritis	NULL
synovial	NULL
1800	NULL
38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44.	NULL
membrane	NULL
contains	NULL
a	NULL
62,000-molecular-weight	NULL
protein	NULL
that	NULL
shares	NULL
an	NULL
antigeme	NULL
epitope	NULL
with	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
encoded	NULL
EBNA-1	NULL
antigen	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
,	NULL
77:1539-1547	NULL
.	NULL

Roudier	NULL
,	NULL
J.	NULL
,	NULL
G.	NULL
Rhodes	NULL
,	NULL
J.	NULL
Petersen	NULL
,	NULL
J.	NULL
H.	NULL
Vaughan	NULL
,	NULL
and	NULL
D.A	NULL
.	NULL

Carson	NULL
.	NULL

1988	NULL
,	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
glycoprotein	NULL
gpl10	NULL
,	NULL
a	NULL
molecular	NULL
link	NULL
between	NULL
HLA	NULL
DRA	NULL
,	NULL
HLA	NULL
DR1	NULL
and	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:367-371	NULL
.	NULL

Alspaugh	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
G.	NULL
Henle	NULL
,	NULL
ET	NULL
.	NULL

Lennette	NULL
,	NULL
and	NULL
W.	NULL
Henle	NULL
.	NULL

1981	NULL
.	NULL

Elevated	NULL
levels	NULL
of	NULL
antibodies	NULL
to	NULL
Epsteim-Barr	NULL
virus	NULL
antigens	NULL
in	NULL
sera	NULL
and	NULL
synovial	NULL
fluids	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Iivest	NULL
.	NULL

67:1134-1140	NULL
.	NULL

Venables	NULL
,	NULL
P.J.W	NULL
.	NULL

1992	NULL
.	NULL

Antibodies	NULL
to	NULL
EBV-encoded	NULL
proteins	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

/n	NULL
Rheumatord	NULL
Arthnts	NULL
.	NULL

E.	NULL
Smolen	NULL
,	NULL
J.	NULL
Kalden	NULL
,	NULL
and	NULL
R.N	NULL
.	NULL

Maini	NULL
,	NULL
editors	NULL
.	NULL

Springer-Verlag	NULL
,	NULL
Berlin	NULL
.	NULL

281-295	NULL
.	NULL

Bardwick	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
H.G	NULL
.	NULL

Bluestein	NULL
,	NULL
N.J.	NULL
Zvaifler	NULL
,	NULL
J.	NULL
Depper	NULL
,	NULL
and	NULL
J.	NULL
Seeginiller	NULL
.	NULL

1979	NULL
.	NULL

Altered	NULL
regulation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
induced	NULL
lymphoblast	NULL
proliferation	NULL
in	NULL
rheumatoid	NULL
arthritus	NULL
lymphoid	NULL
cells	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

23:626-632	NULL
.	NULL

Tosato	NULL
,	NULL
G.	NULL
,	NULL
A.D.	NULL
Steinberg	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Rlacse	NULL
.	NULL

1981	NULL
.	NULL

Defective	NULL
EBV-specific	NULL
suppressor	NULL
T	NULL
cell	NULL
function	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

238-1243	NULL
.	NULL

Kief	NULL
,	NULL
E.	NULL
1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
replication	NULL
.	NULL

In	NULL
Fields	NULL
Virology	NULL
.	NULL

B.N	NULL
.	NULL

Fields	NULL
,	NULL
D.M	NULL
.	NULL

Kmipe	NULL
,	NULL
P.M.	NULL
Howley	NULL
et	NULL
al	NULL
.	NULL

Raven	NULL
Press	NULL
.	NULL

Phuladelphia	NULL
.	NULL

2343-2395	NULL
.	NULL

Lacerda	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
M.	NULL
Ladanyi	NULL
,	NULL
D.C.	NULL
Louie	NULL
,	NULL
J.M	NULL
.	NULL

Fernandez	NULL
,	NULL
EB	NULL
.	NULL

Papadopoulos	NULL
,	NULL
and	NULL
R.	NULL
O'Reilly	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
EBV-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
home	NULL
preferentially	NULL
to	NULL
and	NULL
induce	NULL
selective	NULL
regressions	NULL
of	NULL
autologous	NULL
EBV-induced	NULL
B	NULL
cell	NULL
lym-phoproliferations	NULL
in	NULL
xenografted	NULL
C.B.-17	NULL
seid/seid	NULL
muce	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:1215-1228	NULL
.	NULL

Ant-EBV	NULL
T	NULL
Cell	NULL
Responses	NULL
in	NULL
Rheumatoid	NULL
Arthritis	NULL

